Hyoscine Butylbromide (Buscopan)

Authoritative Clinical Reference

Non-selective Antimuscarnic - Peripheral Acting

DRUG NAME: Hyoscine Butylbromide (Scopolamine Butylbromide)

INN: Hyoscine butylbromide
Also known as: Butylscopolamine, scopolamine butylbromide
USAN equivalent: Scopolamine butylbromide (the term “butylscopolamine” is used in some European pharmacopoeias)

⚠️ CRITICAL DISTINCTION — do NOT confuse with hyoscine hydrobromide (scopolamine):

Property	Hyoscine Butylbromide (THIS monograph)	Hyoscine Hydrobromide
Chemical type	Quaternary ammonium compound	Tertiary amine
Crosses blood-brain barrier?	⛔ NO	Yes
Central (CNS) effects	NONE — no sedation, no amnesia, no antiemetic action	Sedation, amnesia, antiemetic
Site of action	Peripheral muscarinic receptors only (GI, GU, salivary)	Both central and peripheral muscarinic receptors
Primary clinical use	GI/GU antispasmodic	Premedication, motion sickness, antiemetic, palliative antisecretory
Brand most associated	Buscopan	No single dominant brand in India

These two drugs have fundamentally different pharmacological profiles despite sharing the “hyoscine” name. Prescribing errors between the two are documented. If central effects are needed (antiemetic, sedation, amnesia), hyoscine butylbromide will be ineffective. If only peripheral antispasmodic effect is needed, hyoscine hydrobromide will produce unnecessary and potentially dangerous CNS effects (sedation, delirium, especially in the elderly).

Therapeutic Class: Antispasmodic

Subclass

Quaternary Ammonium Antimuscarinic (Peripherally-Acting)

Distinguishes this drug from tertiary amine antimuscarinics (atropine, hyoscine hydrobromide, dicyclomine) that cross the BBB and produce CNS effects, and from direct smooth muscle relaxants (mebeverine, drotaverine, papaverine) that act via non-antimuscarinic mechanisms.

Schedule (India):

Schedule H

All formulations (oral tablets, injection) are Schedule H drugs. A valid prescription is required for dispensing in India.

ℹ️ Note: In several countries (UK, Australia, Germany), hyoscine butylbromide tablets are available OTC for self-treatment of abdominal cramps. In India, no OTC status exists — all formulations require a prescription.

Route(s):

Oral (tablets — swallowed whole)
IV (intravenous — bolus injection)
IM (intramuscular)
Rectal (suppository — very limited availability in India)

ℹ️ The oral route is the most commonly used in outpatient Indian practice. The IV/IM route is used in emergency departments, endoscopy suites, operating theatres, and inpatient settings for acute colic or as a diagnostic adjunct.

Biosimilar Status:

Not a biologic — biosimilar classification not applicable. Hyoscine butylbromide is a small-molecule chemical drug (semi-synthetic quaternary ammonium derivative of the tropane alkaloid hyoscine).

Formulations Available in India:

Single-ingredient formulations:

Dosage Form	Strengths Available	Notes
Tablets (film-coated)	10 mg, 20 mg	10 mg is the standard tablet strength — very widely available across India. 20 mg tablets are less commonly stocked. Tablets should be swallowed whole; film coating prevents bitter taste.
Injection (ampoule)	20 mg/mL (1 mL ampoule)	Clear, colourless solution for IV or IM injection. Widely available in hospital pharmacies and emergency departments.
Suppository (rectal)	10 mg	Very limited availability in India. Not commonly stocked in most Indian pharmacies. Rectal route is culturally less accepted in many Indian patient populations. Primarily available through select pharmacies in metros or by special order.

Fixed-dose combinations (FDCs):

FDC	Strengths	Notes
FDC with paracetamol: Hyoscine butylbromide 10 mg + Paracetamol 500 mg	Standard combination	CDSCO-approved and widely prescribed. Brand: Buscopan Plus (Sanofi). Indicated for spasmodic abdominal pain where both antispasmodic and analgesic effects are desired (e.g., menstrual cramps, biliary colic, renal colic). Widely available across India.

ℹ️ Note on other FDCs: Some FDCs combining hyoscine butylbromide with other analgesics (diclofenac, aceclofenac) or with simethicone have been marketed. Prescribers should verify CDSCO approval status of specific FDC combinations before prescribing, as FDC regulations have undergone significant changes. Refer to the latest CDSCO gazette notifications for the current list of approved and banned FDCs.

Banned/withdrawn formulations: No specific ban on single-ingredient hyoscine butylbromide formulations has been identified. Some irrational FDCs containing hyoscine butylbromide with multiple active ingredients have been included in CDSCO FDC ban lists — prescribers should verify individual FDC products against the latest CDSCO notifications.

PHARMACOKINETICS

The most important pharmacokinetic feature of hyoscine butylbromide is its near-zero oral bioavailability. As a permanently charged quaternary ammonium compound, it is poorly absorbed from the GI tract. When given orally, its clinical effect on GI spasm is primarily through local (intraluminal) muscarinic receptor blockade in the gut wall, NOT through systemic absorption.

Primary pharmacokinetic parameters:

Parameter	Value
Bioavailability (oral)	<1% (extremely poor systemic absorption). The drug acts locally within the GI tract lumen when given orally. The fraction that is absorbed (<1%) does reach the systemic circulation, but plasma levels are very low and clinically insignificant for systemic effect. This is the defining pharmacokinetic characteristic of this drug.
Bioavailability (parenteral)	IV: 100%. IM: near-complete absorption from the injection site. Parenteral routes achieve systemic plasma concentrations and exert peripheral antimuscarinic effects systemically (GI, GU, salivary, sweat glands).
Tmax	Oral: approximately 2 hours (for the minimal fraction absorbed; clinical onset of local GI effect is faster — 15–30 minutes). IV: immediate. IM: approximately 30 minutes.
Protein binding	Low — approximately 4.4%. The low protein binding means that changes in albumin levels (as in liver disease, nephrotic syndrome) do NOT significantly alter free drug levels.
Volume of distribution (Vd)	Approximately 128 L after IV administration (~1.7 L/kg). Distributes widely to peripheral tissues. ⛔ Does NOT cross the blood-brain barrier (quaternary ammonium — permanently charged at physiological pH). Does NOT significantly enter the CNS.
Metabolism	Hepatic — primarily by hydrolysis of the ester bond. No clinically significant CYP450 involvement. Hyoscine butylbromide is not a significant CYP450 inhibitor or inducer at therapeutic doses. Drug transporter interactions: Data limited; formal studies on P-glycoprotein, OATP, BCRP, OAT, OCT, or MATE transporter interactions are not well-documented for hyoscine butylbromide. Given its quaternary ammonium structure, it may be a substrate for organic cation transporters (OCTs), but the clinical significance is unknown.
Active metabolites	No clinically significant active metabolites identified. Metabolites are pharmacologically inactive.
Half-life (t½)	Approximately 5 hours (range reported: 1–5 hours across different studies; terminal half-life approximately 5 hours after IV administration). Data on prolongation in renal or hepatic impairment is limited.
Excretion	Renal and faecal. After IV administration, approximately 50% excreted renally (mainly as metabolites, with a small fraction as unchanged drug) and approximately 28% in faeces. After oral administration, the vast majority of the dose is excreted unchanged in the faeces (not absorbed).
Dialysability	Data limited. Given the large Vd (~128 L) and low protein binding (~4.4%), the drug is unlikely to be significantly removed by haemodialysis. However, formal dialysis clearance data is not available.
Food effect	No clinically significant food effect on the oral formulation. Tablets may be taken with or without food. Since the oral drug acts primarily locally in the GI lumen, food is unlikely to significantly alter clinical efficacy for GI spasm.
Onset of action	Oral: 15–30 minutes (local GI antispasmodic effect). IV: within 1–5 minutes (systemic peripheral antimuscarinic effect). IM: 15–30 minutes.
Duration of action	Approximately 4–6 hours (oral, single dose). After IV, the antispasmodic effect lasts approximately 15–30 minutes (shorter due to rapid redistribution), which is relevant for diagnostic/endoscopic use where brief spasm relief is needed. Repeated doses or higher doses prolong the effect.

Special pharmacokinetic notes:

Local vs systemic action — the critical distinction for oral dosing: When hyoscine butylbromide is taken orally, <1% is absorbed. The clinical antispasmodic effect in the GI tract is due to the drug acting on muscarinic receptors in the gut wall from the luminal side, as the drug passes through the GI tract. This is fundamentally different from most other drugs, where oral dosing implies systemic absorption → systemic distribution → target organ effect. For hyoscine butylbromide, the oral tablet essentially acts as a “topical” drug for the GI tract.
Implication for non-GI indications (oral route): Because oral hyoscine butylbromide has negligible systemic absorption, oral tablets will NOT be effective for conditions requiring systemic antimuscarinic action (e.g., urinary tract spasm, biliary spasm where the spasm is at the sphincter of Oddi — which requires systemic drug levels). For these indications, the parenteral route (IV/IM) must be used to achieve adequate systemic drug levels. This is a common prescribing error in Indian practice.
Non-linear PK: No clinically significant non-linear pharmacokinetics have been reported at therapeutic doses.
Placental transfer: Data limited. The quaternary ammonium structure suggests limited placental transfer, but some degree of transfer cannot be excluded. See Pregnancy section.
Breast milk excretion: Data limited. Given the quaternary ammonium structure, transfer into breast milk is expected to be minimal.

Population Pharmacokinetic Notes:

Population	PK Consideration
Elderly (≥60 years)	No formal PK studies in elderly. Expected to have similar local GI effect (oral) since systemic absorption is minimal. After parenteral administration, reduced renal function may modestly prolong elimination of the small systemically absorbed fraction. Clinical significance is low. However, elderly patients are more sensitive to peripheral anticholinergic effects (urinary retention, constipation, tachycardia, dry mouth).
Paediatric	Limited formal paediatric PK data. Oral bioavailability is assumed to be similarly poor. Weight-based dosing is standard for injectable use. The absence of CNS effects makes it better tolerated than tertiary amine antimuscarinics in children.
Pregnancy	No formal pregnancy PK studies. Quaternary ammonium structure limits placental transfer, but extent of limitation is not well quantified.
Obesity	Data limited. The large Vd (~128 L) suggests wide tissue distribution; dosing adjustments based on actual body weight vs ideal body weight have not been formally studied. For parenteral dosing, use standard fixed doses (not weight-based) as per approved labelling.
Renal impairment	Reduced renal clearance may prolong elimination of systemically absorbed drug. Since oral bioavailability is <1% and the drug acts locally, renal impairment is unlikely to affect the efficacy or safety of oral dosing significantly. For parenteral use, use with caution in severe renal impairment and monitor for prolonged anticholinergic effects.
Hepatic impairment	Hepatic hydrolysis is the primary metabolic pathway. Severe hepatic impairment may reduce clearance of systemically absorbed drug. For oral dosing (local action), hepatic impairment is unlikely to be clinically significant. For parenteral dosing, use with caution.
Critical illness / ICU	Data limited. In critically ill patients, altered splanchnic blood flow may theoretically affect local GI drug exposure from oral dosing. Parenteral dosing is preferred in ICU settings. Anticholinergic effects on gut motility may compound existing ileus in ICU patients.

ADULT INDICATIONS + DOSING FOR CLINICIAN USE ONLY

⛔ This section is a clinical reference for qualified prescribers only. Not for self-medication or patient self-dosing.

Primary Indications (Approved / Standard in India)

1. SPASMODIC ABDOMINAL PAIN — GI TRACT (Including IBS-Related Spasm, Functional Abdominal Cramps, Gastric/Intestinal Spasm)

Clinical context: Hyoscine butylbromide relieves smooth muscle spasm in the gastrointestinal tract by blocking muscarinic receptors (predominantly M₃ subtype) on the smooth muscle cells of the stomach, duodenum, jejunum, ileum, and colon. When given orally, it acts locally from the GI lumen with negligible systemic absorption (<1%). This makes the oral route effective for GI spasm specifically (unlike urological or biliary spasm, where systemic levels are needed).

Multi-route dosing table — Adults:

Route	Starting Dose	Titration	Usual Maintenance Dose	Maximum Dose	Clinical Notes
Oral (preferred for outpatient GI spasm)	10 mg three times daily	Increase to 20 mg per dose if 10 mg is insufficient after 2–3 days	10–20 mg three to four times daily	Max 20 mg per dose; Max 80 mg per day (some CDSCO product inserts permit up to 60 mg/day in 3 divided doses; Sanofi Buscopan insert permits up to 80 mg/day in 4 divided doses — follow the specific product insert).	Take 30 minutes before meals for best effect on meal-related spasm. Swallow whole with water. Acts within 15–30 minutes. Duration approximately 4–6 hours.
IV (for acute severe colic in emergency/inpatient setting)	20 mg as a single IV bolus dose	May repeat after 30 minutes if spasm persists	Usually a single dose or 2–3 doses as needed	Max 20 mg per dose; Max 100 mg per day (IV/IM combined total daily dose)	Administer slowly over 1–2 minutes. Onset within 1–5 minutes. Duration of IV effect is shorter (~15–30 minutes); repeat dosing may be needed. For acute abdomen — rule out surgical causes before treating pain with antispasmodics.
IM	20 mg as a single IM injection	May repeat after 30 minutes if needed	Single dose or up to 3–5 doses per day depending on clinical need	Max 20 mg per dose; Max 100 mg per day	Inject into deltoid or gluteal muscle. Onset approximately 15–30 minutes. Used when IV access is not available.
Rectal (suppository)	10 mg as a single suppository	May repeat after 6–8 hours if needed	10 mg two to three times daily	Max 10 mg per dose; Max 30 mg per day (rectal)	⚠️ Very limited availability in India. Culturally less accepted. Consider when oral route is unavailable (vomiting) and parenteral route is not accessible. Insert high into the rectum.

ℹ️ Route selection guidance for GI spasm:

Mild-to-moderate GI cramps (outpatient/OPD): Oral tablets — effective, safe, and affordable.
Severe acute GI colic (emergency department): IV bolus — fastest onset; provides diagnostic value (if spasm resolves with antispasmodic, less likely to be a surgical abdomen).
Vomiting patient who cannot take oral medication and IV access unavailable: IM injection or rectal suppository (if available).

Mandatory Clinical Notes:

When to prefer this drug over alternatives:
- Prefer over dicyclomine when a drug with no CNS effects is needed (dicyclomine crosses the BBB and causes drowsiness; hyoscine butylbromide does not). This is especially important for patients who drive, operate machinery, or need to remain alert.
- Prefer over atropine for GI spasm because atropine has significant systemic anticholinergic effects (tachycardia, mydriasis, urinary retention, CNS effects) at antispasmodic doses.
- Prefer over drotaverine or mebeverine when an antimuscarinic mechanism is specifically needed (e.g., confirmed muscarinic-mediated spasm, or when direct smooth muscle relaxants have been ineffective).
- ℹ️ Drotaverine (Drotin) is more commonly used in Indian emergency departments for acute colic than hyoscine butylbromide, primarily due to familiarity and availability. Both are acceptable choices; hyoscine butylbromide has a longer history of use and a different mechanism (antimuscarinic vs PDE-4 inhibition).
When NOT to use even though technically indicated:
- ⚠️ Mechanical bowel obstruction or suspected surgical abdomen — antispasmodics may mask symptoms and delay surgical intervention. Always rule out surgical causes of acute abdominal pain before administering antispasmodics.
- Paralytic ileus — anticholinergic drugs worsen GI stasis.
- Toxic megacolon — risk of worsening dilation and perforation.
- Patients with myasthenia gravis (antagonises cholinesterase inhibitors).
- Patients with untreated narrow-angle glaucoma (parenteral route — systemic anticholinergic effect; oral route risk is minimal due to negligible absorption).
NLEM India status: Hyoscine butylbromide is NOT listed in NLEM India 2022. Dicyclomine is listed as an antispasmodic in the NLEM. Drotaverine is also not listed.
Typical time to expected clinical response:
- Oral: 15–30 minutes for onset; full effect within 30–60 minutes.
- IV: 1–5 minutes.
- IM: 15–30 minutes.
- If no response within 30 minutes (oral) or 15 minutes (IV), consider alternative diagnosis (e.g., surgical abdomen) or alternative drug.
Criteria for treatment failure and switching:
- If 3–5 days of oral hyoscine butylbromide at maximum doses fails to relieve recurrent GI spasm, consider:
  - Re-evaluation of diagnosis (is the pain truly spasmodic?).
  - Trial of mebeverine (135 mg TDS — direct smooth muscle relaxant, better tolerated long-term for IBS) or drotaverine (80 mg TDS).
  - Trial of peppermint oil capsules (enteric-coated — evidence for IBS-related spasm).
  - Gastroenterology referral if symptoms are persistent, progressive, or associated with red flags (weight loss, bleeding, anaemia, age >45 with new symptoms).
- For acute colic unresponsive to IV hyoscine butylbromide, switch to IV drotaverine 40–80 mg or consider opioid analgesia (tramadol/morphine) with appropriate monitoring.
Mandatory baseline investigations:
- No mandatory laboratory investigations before starting oral hyoscine butylbromide for self-limiting GI cramps.
- RECOMMENDED before IV use in acute abdomen: Basic blood panel (CBC, electrolytes, serum amylase/lipase if pancreatitis suspected), abdominal X-ray (to rule out perforation/obstruction), and clinical assessment for peritonitis.
- MANDATORY: Clinical assessment to exclude surgical abdomen before attributing pain to spasm.
Specialist initiation:Not required for oral use. Any registered medical practitioner can prescribe. IV use is typically in the emergency department or inpatient setting supervised by an attending physician.
Indian guideline source: API Textbook of Medicine (current edition) mentions antispasmodics for functional GI disorders and IBS; hyoscine butylbromide is listed as an option. Indian Society of Gastroenterology (ISG) IBS Consensus Statement (2018) includes antispasmodics as a treatment option for abdominal cramps in IBS, without specifying a single preferred agent. No specific ICMR guideline addresses antispasmodic choice.
Key disease-specific safety warning: ⚠️ IBS-specific: Hyoscine butylbromide provides symptom relief only — it does not modify the underlying disease process in IBS. It is most effective for the cramping/pain component of IBS; it does not treat diarrhoea, constipation, or bloating. It may worsen constipation-predominant IBS (IBS-C) through its antimotility effect. Prefer mebeverine for IBS-C patients. Hyoscine butylbromide is better suited for IBS-D (diarrhoea-predominant) or IBS-M (mixed) where both spasm relief and mild reduction in GI motility are desirable.
Common dose adjustment scenarios:
- Elderly: No formal dose adjustment for oral use (negligible systemic absorption). For parenteral use, use standard dose with monitoring for tachycardia and urinary retention. See ELDERLY section.
- Renal impairment: No adjustment for oral use. Use parenteral route with caution in severe renal impairment — monitor for prolonged anticholinergic effects.
- Hepatic impairment: No adjustment for oral use. Parenteral use — use with caution in severe hepatic impairment.
- Concurrent anticholinergic drugs: Reduce dose or avoid if patient is already on multiple anticholinergics.

2. RENAL COLIC / URETERIC SPASM

Clinical context: Hyoscine butylbromide relaxes ureteric and bladder smooth muscle via muscarinic receptor blockade, relieving the spasmodic component of renal/ureteric colic. The parenteral route is preferred for acute colic because systemic drug levels are needed to reach ureteric smooth muscle (oral bioavailability <1% — oral route will NOT achieve adequate systemic levels for ureteric spasm relief).

Dosing table — Adults:

Route	Starting Dose	Titration	Usual Maintenance Dose	Maximum Dose	Clinical Notes
IV (preferred for acute renal colic)	20 mg as a single IV bolus	May repeat 20 mg after 30 minutes if colic persists	20–40 mg per episode (1–2 doses)	Max 20 mg per dose; Max 100 mg per day (total parenteral)	Administer slowly over 1–2 minutes. Usually combined with an analgesic (diclofenac 75 mg IM, or paracetamol 1 g IV) for optimal pain control. Hyoscine butylbromide alone is usually insufficient for moderate-to-severe renal colic.
IM	20 mg as a single IM injection	May repeat after 30 minutes if needed	20–40 mg per episode	Max 20 mg per dose; Max 100 mg per day	Used when IV access is not immediately available. Slightly slower onset than IV.
Oral	⚠️ NOT recommended for acute renal colic	—	—	—	⚠️ Oral hyoscine butylbromide has negligible systemic bioavailability (<1%). It will NOT achieve therapeutic systemic drug levels needed to relax ureteric smooth muscle. Prescribing oral hyoscine butylbromide for renal colic is a common prescribing error in Indian practice. The oral route may have a minor adjunctive role once acute colic has resolved (preventing recurrent mild spasm while awaiting stone passage), but evidence for this is weak.

ℹ️ Evidence context — antispasmodics in renal colic: Systematic reviews (including Cochrane) suggest that antispasmodics provide modest additional benefit over NSAIDs alone for renal colic. NSAIDs (diclofenac 75 mg IM or 50 mg PO) remain the first-line analgesic. Hyoscine butylbromide is commonly added as an adjunct in Indian emergency departments. Some studies suggest drotaverine may be more effective than hyoscine butylbromide for ureteric colic, but head-to-head evidence is limited.

Mandatory Clinical Notes:

When to prefer over alternatives: Consider as an adjunct to NSAIDs in acute renal colic. Prefer over drotaverine if the clinician desires a specifically antimuscarinic mechanism. However, drotaverine (40–80 mg IV) is more commonly used in Indian emergency departments for renal colic and has some evidence for superior efficacy. The choice is often based on institutional protocol and clinician preference.
When NOT to use:
- Do NOT use oral tablets expecting systemic antispasmodic effect on ureters — prescribe parenteral formulation.
- Do NOT use as a substitute for adequate analgesia — antispasmodic alone is insufficient for moderate-to-severe colic.
- Suspected obstructive uropathy with anuria — urgent urology/nephrology referral, not antispasmodic therapy.
- Concurrent sepsis with renal calculus (pyonephrosis) — requires urgent drainage, not antispasmodic.
NLEM India status: Not listed. Diclofenac injection is listed in NLEM for acute pain management.
Time to response: IV: 1–5 minutes. If no response within 15 minutes after IV dose, consider repeating once. If still unresponsive, escalate analgesic therapy (opioids — tramadol 50–100 mg IV, or morphine 2–5 mg IV in titrated doses).
Treatment failure criteria: If colic persists despite 2 doses of IV hyoscine butylbromide + adequate analgesia, consider: obstructing stone requiring intervention, alternative diagnosis (AAA, mesenteric ischaemia, ovarian torsion), or urology referral for DJ stent/percutaneous nephrostomy.
Mandatory baseline investigations:
- MANDATORY: Urine analysis (haematuria supports stone diagnosis), serum creatinine (rule out AKI from obstruction), ultrasound KUB (detect hydronephrosis).
- RECOMMENDED: Non-contrast CT KUB (gold standard for stone detection — availability varies in Indian centres). CBC (rule out infection). Serum electrolytes.
Specialist initiation: Not required for initial emergency management. Urology referral for stones >5–6 mm, obstructive features, recurrent colic, or suspected complicated stone disease.
Indian guideline source: Urological Society of India (USI) guidelines on urolithiasis management recommend NSAIDs as first-line analgesia with antispasmodics as adjunctive therapy. API Textbook of Medicine references antispasmodics for colic management.
Key safety warning: ⚠️ Do NOT delay imaging and definitive management by repeated antispasmodic dosing. Renal colic with associated sepsis (fever, rigors, pyuria) or anuria requires EMERGENCY urological intervention, not continued antispasmodic therapy.
Dose adjustment: No adjustment for the typical 1–2 parenteral doses used in acute colic. Avoid repeated dosing in patients with severe renal impairment.

3. BILIARY COLIC / BILIARY SPASM

Clinical context: Hyoscine butylbromide relaxes biliary smooth muscle (gallbladder, bile ducts, and sphincter of Oddi) through muscarinic receptor blockade. The parenteral route is essential for biliary spasm because systemic drug levels are needed to reach the biliary system.

Dosing table — Adults:

Route	Starting Dose	Titration	Usual Maintenance Dose	Maximum Dose	Clinical Notes
IV (preferred for acute biliary colic)	20 mg as a single IV bolus	May repeat 20 mg after 30 minutes if spasm persists	20–40 mg per episode	Max 20 mg per dose; Max 100 mg per day	Usually combined with an NSAID (diclofenac 75 mg IM) or paracetamol IV. Onset within 1–5 minutes.
IM	20 mg as a single IM injection	May repeat after 30 minutes	20–40 mg per episode	Max 20 mg per dose; Max 100 mg per day	Alternative when IV access unavailable.
Oral	⚠️ NOT effective for acute biliary colic	—	May be used as adjunct BETWEEN episodes (10–20 mg TDS) for mild recurrent biliary dyspepsia while awaiting cholecystectomy	Max 20 mg per dose; Max 80 mg per day	Same limitation as for renal colic — negligible systemic absorption. May have minor role in preventing meal-related biliary discomfort. Evidence is weak.

Mandatory Clinical Notes:

Prefer over alternatives: Hyoscine butylbromide is one of the most commonly used antispasmodics for biliary colic in Indian emergency departments. Alternative: drotaverine 40–80 mg IV. Both are acceptable; choice is institution-dependent. ℹ️ Morphine was historically avoided in biliary colic due to theoretical sphincter of Oddi spasm, but current evidence suggests this concern is overstated. If pain is severe, opioids (with or without antispasmodic) should NOT be withheld based on this outdated concern.
When NOT to use: Suspected cholangitis (Charcot’s triad — pain, fever, jaundice) — requires urgent biliary drainage. Suspected gallbladder perforation or biliary peritonitis — surgical emergency. Do NOT delay cholecystectomy referral by relying on chronic antispasmodic therapy for recurrent biliary colic.
NLEM status: Not listed.
Time to response: IV: 1–5 minutes.
Treatment failure: Persistent colic despite antispasmodic + analgesic → reassess diagnosis (acute cholecystitis? choledocholithiasis? pancreatitis?); surgical/gastroenterology referral.
Baseline investigations: MANDATORY: LFT, serum amylase/lipase (rule out pancreatitis), USG abdomen. RECOMMENDED: CBC (leucocytosis if cholecystitis).
Specialist initiation: Not required for acute management. Surgical referral for definitive management (cholecystectomy).
Indian source: API Textbook of Medicine; standard surgical textbooks used in Indian practice (SRB’s Manual of Surgery, Bailey & Love).
Safety warning: ⚠️ Anticholinergic drugs may theoretically delay gallbladder emptying with chronic use. Do NOT use chronic oral hyoscine butylbromide as a substitute for cholecystectomy in symptomatic gallstone disease.
Dose adjustment: Standard dosing for acute episode. No special adjustment.

4. DYSMENORRHOEA (Menstrual Cramps)

Clinical context: Hyoscine butylbromide relieves uterine smooth muscle spasm during menstruation. Both oral and parenteral routes are used. Oral tablets are the mainstay for outpatient management of primary dysmenorrhoea. The FDC with paracetamol (Buscopan Plus: hyoscine butylbromide 10 mg + paracetamol 500 mg) is widely prescribed for this indication in Indian practice.

Dosing table — Adults:

Route	Starting Dose	Titration	Usual Maintenance Dose	Maximum Dose	Clinical Notes
Oral (for primary dysmenorrhoea — outpatient)	10 mg three times daily (or FDC with paracetamol: 1 tablet TDS)	Increase to 20 mg per dose if 10 mg insufficient	10–20 mg three to four times daily	Max 20 mg per dose; Max 80 mg per day	Start on the first day of menstruation (or the day before if pain is predictable). Take 30 minutes before meals. Continue for 2–3 days or until cramps resolve.
IV/IM (for severe dysmenorrhoea in emergency)	20 mg IV bolus or IM	May repeat once after 30 minutes	Usually a single episode dose	Max 20 mg per dose; Max 100 mg per day	Rarely needed. Usually reserved for severe dysmenorrhoea unresponsive to oral NSAIDs + oral antispasmodics.

Mandatory Clinical Notes:

When to prefer over alternatives: Consider when NSAIDs alone are insufficient for dysmenorrhoea, or when NSAIDs are contraindicated/not tolerated (e.g., peptic ulcer disease, NSAID allergy, aspirin-exacerbated respiratory disease). The FDC with paracetamol (Buscopan Plus) provides dual analgesic + antispasmodic action and is a reasonable first-choice for mild-to-moderate primary dysmenorrhoea. NSAIDs (mefenamic acid 500 mg TDS, ibuprofen 400 mg TDS) remain the first-line treatment for moderate-to-severe primary dysmenorrhoea supported by stronger evidence.
When NOT to use: Secondary dysmenorrhoea (endometriosis, adenomyosis, fibroids) requires definitive gynaecological management — antispasmodics provide symptomatic relief only and should NOT delay workup. Red flags: progressively worsening dysmenorrhoea, heavy menstrual bleeding, intermenstrual bleeding, infertility — warrant gynaecological referral.
NLEM status: Not listed. Mefenamic acid and ibuprofen are available in NLEM as analgesics.
Time to response: Oral: 15–30 minutes.
Treatment failure: If cramps persist despite 3 days of maximal-dose hyoscine butylbromide + NSAID, reassess for secondary causes. Consider hormonal therapy (combined OCP, IUS) for recurrent severe primary dysmenorrhoea — gynaecology referral.
Baseline investigations: None mandatory for primary dysmenorrhoea in young women with typical history. If secondary causes suspected: pelvic ultrasound.
Specialist initiation: Not required. Primary care appropriate.
Indian source: FOGSI (Federation of Obstetric and Gynaecological Societies of India) practice guidance on dysmenorrhoea management.
Safety warning: No specific disease-related safety warning unique to dysmenorrhoea beyond standard anticholinergic cautions.
Dose adjustment: Standard dosing. Self-limiting course (2–3 days/month).

5. ADJUNCT IN GASTROINTESTINAL ENDOSCOPY AND RADIOLOGICAL PROCEDURES (Diagnostic/Therapeutic Antispasmodic)

Clinical context: IV hyoscine butylbromide is used during upper GI endoscopy (EGD), colonoscopy, ERCP, CT/MRI enterography, and barium studies to reduce GI motility and spasm, improving mucosal visualisation, facilitating endoscopic manoeuvres (polypectomy, biopsy), and reducing motion artefact on imaging. It is administered as a single IV bolus at the time of the procedure.

Dosing — Adults:

Route	Dose	Maximum	Clinical Notes
IV (only route used for this indication)	20 mg as a single IV bolus, administered slowly over 1–2 minutes, at the start of the procedure or when bowel spasm is encountered during the procedure	May repeat 20 mg once during the procedure if spasm recurs (total max 40 mg per procedure)	Onset within 1–5 minutes; duration of antispasmodic effect approximately 15–30 minutes — usually sufficient for the procedure. If prolonged procedure, may need repeat dosing. Do NOT use oral route — systemic levels are needed.

ℹ️ Alternative: Glucagon 1 mg IV is used in some centres internationally as an alternative antispasmodic for endoscopy. In India, glucagon injection is expensive and not widely stocked for this purpose. Hyoscine butylbromide is the standard and most affordable choice in Indian endoscopy practice.

Mandatory Clinical Notes:

When to prefer: Standard agent for GI endoscopy antispasmodic support in India. Preferred over glucagon due to cost and availability. Preferred over hyoscine hydrobromide because CNS effects (sedation, amnesia) from hyoscine hydrobromide are undesirable during endoscopy where the patient’s cooperation is needed (especially in unsedated or lightly sedated endoscopy, which is still common in many Indian centres).
When NOT to use: Patients with unstable cardiac rhythm — tachycardia from anticholinergic effect may be hazardous. Not all endoscopic procedures require antispasmodic — routine diagnostic EGD in a cooperative patient often does not need it. Used selectively when spasm impairs visualisation or when ERCP requires sphincter relaxation.
NLEM status: Not listed.
Time to response: 1–5 minutes IV.
Treatment failure: If spasm persists despite 40 mg IV, consider glucagon 0.5–1 mg IV (if available). Alternatively, accept suboptimal visualisation and repeat procedure if needed.
Baseline investigations: Standard pre-endoscopy assessment (coagulation profile, consent). No specific investigation for the antispasmodic component.
Specialist initiation: Used by gastroenterologists, endoscopists, and radiologists during procedures. Not a primary care prescription.
Indian source: Indian Society of Gastroenterology (ISG) endoscopy practice — standard institutional protocols. ESGE (European Society of Gastrointestinal Endoscopy) guidelines referenced for procedural standards adapted to Indian practice.
Safety warning: ⚠️ Tachycardia: Monitor heart rate. In patients with pre-existing tachycardia or ischaemic heart disease, the additional heart rate increase from IV hyoscine butylbromide may be poorly tolerated. Use with caution in such patients — consider proceeding without antispasmodic or using glucagon (which does not cause tachycardia). ⚠️ Urinary retention post-procedure: Particularly in elderly males with BPH. Ensure the patient has voided before discharge from the endoscopy unit.
Dose adjustment: No dose adjustment needed for this single-dose procedural use. Use standard 20 mg IV.

Secondary Indications — Adults Only (Off-label)

1. ACCELERATION OF CERVICAL DILATION IN LABOUR

OFF-LABEL — commonly used in Indian obstetric practice but evidence remains controversial

Clinical context: Hyoscine butylbromide injection (20 mg IV or IM) is widely used in Indian labour rooms with the intention of accelerating cervical dilation during the active phase of the first stage of labour. The rationale is that muscarinic receptor blockade relaxes the smooth muscle of the cervix, reducing cervical resistance and facilitating dilation.

ℹ️ This is one of the most common off-label uses of hyoscine butylbromide in India. Its use is deeply embedded in Indian obstetric practice, particularly at the district hospital and medical college level. However, the quality of evidence supporting this practice is variable.

Dosing — Adults (Obstetric):

Route	Dose	Maximum	Timing	Notes
IV	20 mg as a single IV bolus (some protocols use 40 mg as a single dose)	Max 40 mg per dose; Max 80 mg total during labour (2 doses separated by ≥30 minutes)	Administered during the active phase of labour (cervical dilation ≥3–4 cm)	Administer slowly over 1–2 minutes. Monitor FHR with CTG during and after administration.
IM	20 mg as a single IM injection	Max 40 mg (may repeat once)	Same timing as IV	Slightly slower onset than IV.
Rectal (suppository)	10 mg — used in some protocols	Max 10 mg per insertion	Same timing	⚠️ Very limited availability. Rarely used.

Evidence basis:

Multiple small Indian RCTs (primarily from medical college hospitals) have evaluated hyoscine butylbromide for cervical dilation. Results are heterogeneous: some studies report a statistically significant reduction in the duration of the active phase of the first stage of labour (by 1–3 hours), while others show no significant benefit.
A Cochrane review on antispasmodics in labour (including hyoscine butylbromide, drotaverine, and valethamate) found low-to-moderate quality evidence suggesting some reduction in labour duration, but the clinical significance was uncertain, and the risk of bias in included studies was substantial.
Drotaverine (Drotin) has better quality evidence for cervical dilation acceleration than hyoscine butylbromide in the Indian literature and is recommended by some FOGSI practice guidelines over hyoscine butylbromide for this purpose.
Level of evidence: Moderate (multiple RCTs exist, but methodological quality is variable; no large, high-quality multicentre trial definitively establishes benefit).

Key clinical notes:

⚠️ FOGSI has not issued a formal consensus guideline endorsing routine use of hyoscine butylbromide for labour augmentation. Some FOGSI publications reference it as an option; others recommend drotaverine as the preferred antispasmodic.
⚠️ Monitor FHR closely — transient fetal tachycardia has been reported (though less frequently than with hyoscine hydrobromide, because hyoscine butylbromide has minimal placental transfer as a quaternary ammonium compound).
⚠️ Maternal tachycardia — monitor. Usually transient and mild.
⚠️ Dry mouth — common; provide oral fluids.
Do NOT use in prelabour / latent phase — no evidence of benefit and may delay recognition of prolonged latent phase.
Do NOT substitute for oxytocin augmentation in cases of inadequate uterine contractions — these are different mechanisms.
Use only in uncomplicated term pregnancies. Contraindicated if caesarean section is planned or if cervical dilation is progressing normally without intervention.

2. TERMINAL RESPIRATORY SECRETIONS (“DEATH RATTLE”) IN PALLIATIVE CARE

OFF-LABEL

Clinical context: Hyoscine butylbromide is used in some palliative care protocols to reduce terminal respiratory secretions. However, it is generally considered less effective than hyoscine hydrobromide for this indication because it does NOT cross the blood-brain barrier and therefore does not provide the concurrent sedation that is often desired in the dying phase. It only reduces peripheral secretion production.

Dosing — Adults (Palliative care):

Route	Dose	Maximum	Notes
SC (subcutaneous — preferred in palliative care) or IV	20 mg every 4–6 hours PRN, OR continuous SC infusion 60–120 mg over 24 hours via syringe driver	Max 20 mg per dose (bolus); Max 120 mg per day (higher doses than standard labelling — palliative care practice)	ℹ️ Note: The doses used in palliative care for terminal secretions often exceed the standard CDSCO-labelled maximum dose (100 mg/day). This is accepted palliative care practice based on the symptom burden in the terminal phase and the wide safety margin of hyoscine butylbromide. However, prescribers should be aware this constitutes off-label dosing.

Evidence basis: Level of evidence: Moderate (multiple studies comparing antisecretory agents in terminal care; hyoscine butylbromide is one of three commonly used drugs — alongside hyoscine hydrobromide and glycopyrrolate). IAPC (Indian Association of Palliative Care) guidelines list all three as options.

💡 Choosing between antisecretory agents for death rattle (palliative care):

Agent	Crosses BBB?	Sedation?	Best suited when…
Hyoscine hydrobromide	Yes	Yes (significant)	Patient is agitated; concurrent sedation is desired
Hyoscine butylbromide	No	No	Patient is still conscious and wishes to communicate; delirium is already present and additional sedation must be avoided
Glycopyrrolate	No	No	Same as hyoscine butylbromide; additionally preferred when the patient is on other medications that may cause additive sedation

3. BLADDER SPASM / DETRUSOR OVERACTIVITY (Adjunctive Use)

OFF-LABEL

Clinical context: Parenteral hyoscine butylbromide has been used to relieve acute bladder spasm (e.g., post-urological surgery, post-catheterisation, bladder irritation from infection or stone). This is an off-label use. Oral hyoscine butylbromide is NOT effective for this indication due to negligible systemic absorption.

Dosing — Adults:

Route	Dose	Maximum	Notes
IV or IM	20 mg every 6–8 hours PRN	Max 20 mg per dose; Max 100 mg per day	Used only for acute bladder spasm in the hospital setting. NOT for chronic overactive bladder management. For chronic OAB, use dedicated antimuscarinics (oxybutynin, tolterodine, solifenacin) or beta-3 agonists (mirabegron).

Evidence basis: Level of evidence: Weak (case series, expert opinion, and standard urology practice; no high-quality RCTs specifically for hyoscine butylbromide in bladder spasm).

4. ADJUNCT IN HYSTEROSALPINGOGRAPHY (HSG) AND OTHER GYNAECOLOGICAL PROCEDURES

OFF-LABEL

Clinical context: IV hyoscine butylbromide (20 mg) is administered before HSG and some other gynaecological diagnostic procedures to reduce tubal and uterine spasm, improving contrast flow and reducing false-positive tubal occlusion results due to spasm.

Dosing — Adults:

Route	Dose	Timing	Notes
IV	20 mg as a single IV bolus	5–10 minutes before the procedure	Reduces tubal spasm, improving diagnostic accuracy. Single-dose use. No repeat needed.

Evidence basis: Level of evidence: Moderate (small RCTs and observational studies support reduced tubal spasm and fewer false-positive results; commonly used in Indian infertility practice).

5. SYMPTOMATIC RELIEF OF DIVERTICULAR SPASM

OFF-LABEL

Clinical context: Oral hyoscine butylbromide is used for symptomatic relief of colonic spasm associated with diverticular disease (without diverticulitis). This is an off-label use in India. The oral route may be partially effective through local luminal action on colonic smooth muscle, similar to its mechanism in IBS.

Dosing — Adults:

Route	Dose	Maximum	Duration	Notes
Oral	10–20 mg three times daily	Max 20 mg per dose; Max 80 mg per day	Short courses (1–2 weeks) during symptomatic flares	Combine with dietary fibre modification (high-fibre diet). Stop if symptoms persist beyond 2 weeks — reassess for complications (abscess, stricture, fistula).

Evidence basis: Level of evidence: Weak (extrapolated from IBS data and clinical practice; no RCTs specifically for hyoscine butylbromide in diverticular spasm).

6. REDUCTION OF SPASM DURING ERCP / SPHINCTER OF ODDI DYSFUNCTION

OFF-LABEL but accepted standard practice in India

Clinical context: During ERCP (endoscopic retrograde cholangiopancreatography), IV hyoscine butylbromide is used to reduce duodenal motility and relax the sphincter of Oddi, facilitating cannulation and stone extraction. This is standard practice in Indian gastroenterology/endoscopy units.

Dosing — Adults:

Route	Dose	Maximum	Notes
IV	20 mg IV bolus at the start of ERCP	May repeat 20 mg once during the procedure (total 40 mg)	Standard procedural adjunct. Same dosing as for diagnostic endoscopy. See Primary Indication 5 for clinical notes.

Evidence basis: Level of evidence: Moderate (supported by international endoscopy guidelines and widespread practice; standard in Indian gastroenterology departments).

Indian source: ISG and SGEI (Society of Gastrointestinal Endoscopy of India) procedural protocols.

PAEDIATRIC DOSING (Specialist Only)

⛔ All paediatric use of hyoscine butylbromide — particularly injectable formulations — should be under specialist supervision (paediatrician, paediatric surgeon, or paediatric gastroenterologist). Oral tablets may be prescribed by a paediatrician for older children with appropriate clinical assessment.

General Notes:

⚠️ Age restriction: Hyoscine butylbromide tablets are NOT recommended in children below 6 years of age per most CDSCO product inserts (including Buscopan, Sanofi). The injectable formulation is generally not recommended in infants below 1 year unless under specialist supervision in a hospital setting.
Safety monitoring requirements specific to paediatric use:
- Monitor heart rate (tachycardia — children may be more sensitive to the chronotropic effect of anticholinergics via systemic absorption from parenteral route)
- Monitor temperature (anticholinergic suppression of sweating — relevant in Indian hot climate, particularly in febrile children)
- Monitor hydration status (dry mouth + reduced fluid intake in unwell children → dehydration risk)
- Monitor for urinary retention (especially postoperative paediatric patients)
- Monitor bowel sounds and abdominal distension (especially in neonates and infants — risk of ileus)
Formulation suitability for children:
- Oral tablet (10 mg): Suitable for children ≥6 years who can swallow tablets whole. Film-coated — should NOT be crushed (bitter taste, no stability data for crushed form). No paediatric oral liquid formulation (syrup/suspension) of hyoscine butylbromide is commercially available in India. This is a significant practical limitation for young children.
- Injectable (20 mg/mL): Can be used in children ≥1 year (some references permit use from 1 month under specialist supervision). Allows accurate weight-based dosing. Requires dilution for small-volume paediatric doses.
- Suppository (10 mg): Very limited availability in India. Not practical for routine paediatric use.
Palatability: Not applicable — no oral liquid formulation exists. Tablets are film-coated and should not be chewed (bitter taste if coating is disrupted).
Age-specific pharmacokinetic differences:
- Oral bioavailability remains negligibly low (<1%) in children, as in adults — the drug acts locally in the GI lumen.
- After parenteral administration, neonates and infants may have prolonged drug effects due to immature hepatic hydrolysis pathways and reduced renal clearance. Use with extra caution in this age group.
- The quaternary ammonium structure ensures NO CNS effects even in children — this is an advantage over dicyclomine (which crosses the BBB and has caused serious CNS adverse events including seizures and apnoea in infants).

Dosing method: Weight-based (mg/kg) for injectable use; fixed age-based dosing for oral tablets (due to limited formulation options).

Adolescent transition: Children ≥12 years AND ≥40 kg may use adult dosing (10–20 mg oral TDS; 20 mg IV/IM). For adolescents 12–18 years weighing <40 kg, use weight-based parenteral dosing with adult maximum ceiling.

Neonatal Dosing (<28 days of life)

⛔ Neonatal use — NICU supervision only

Hyoscine butylbromide use in neonates is NOT part of standard neonatal practice and is rarely indicated. Neonatal gastrointestinal colic (“infantile colic”) should NOT be treated with anticholinergic drugs.

Indication	Dose	Notes
Acute GI spasm (postoperative, e.g., post-Hirschsprung repair) — exceptional use only	0.3–0.5 mg/kg IV as a single dose	⚠️ Specialist use only (neonatal surgeon / neonatologist). Very limited data. Monitor heart rate, temperature, urine output, and bowel function closely. Risk of paralytic ileus in postoperative neonates.
All other neonatal indications	Not recommended	No established neonatal dosing. Use only under specialist supervision with clear clinical justification.

ℹ️ Infantile colic: ⛔ Hyoscine butylbromide is NOT indicated and NOT recommended for infantile colic. The safety profile of anticholinergics in infants <6 months is concerning (risk of apnoea, paradoxical excitation, ileus, temperature dysregulation). Non-pharmacological management (feeding technique modification, simethicone for gas, reassurance) is recommended. Dicyclomine was historically used for infantile colic but was associated with serious adverse events (apnoea, seizures, death) in infants <6 months and is now contraindicated in this age group — the same caution should apply to hyoscine butylbromide.

Primary Indications — Paediatric (Approved / Standard in India)

1. SPASMODIC ABDOMINAL PAIN — GI TRACT (Paediatric)

Clinical context: Hyoscine butylbromide oral tablets are used in children ≥6 years for spasmodic abdominal pain (functional abdominal pain, recurrent abdominal pain of childhood, GI spasm). The injectable formulation is used in the emergency department for acute colic. As in adults, the oral route acts locally in the GI lumen with negligible systemic absorption.

Dosing table — Paediatric:

Age Group	Route	Dose	Maximum	Notes
6–12 years	Oral	10 mg three times daily	Max 10 mg per dose; Max 30 mg per day	Swallow tablet whole with water. Take 30 minutes before meals if pain is meal-related. No dose escalation to 20 mg in this age group (insufficient safety data for higher doses).
≥12 years (≥40 kg)	Oral	10–20 mg three to four times daily	Max 20 mg per dose; Max 80 mg per day	Adult dosing applies.
1–6 years	Oral	⛔ NOT recommended	—	No suitable oral formulation (tablet cannot be accurately dose-split; no liquid available). Do NOT crush the film-coated tablet for administration.
≥1 year (≥10 kg)	IV (acute colic, hospital setting)	0.3–0.5 mg/kg as a single IV bolus (max 20 mg per dose)	Max 0.5 mg/kg per dose; Max 1.5 mg/kg per day (in divided doses every 6–8 hours); absolute maximum 20 mg per dose and 60 mg per day	Administer slowly over 1–2 minutes. Monitor heart rate. Usually a single dose is sufficient. Reserve for severe colic unresponsive to oral analgesics.
≥1 year (≥10 kg)	IM	0.3–0.5 mg/kg as a single IM injection (max 20 mg per dose)	Same maximums as IV	Used when IV access is not available. Inject into anterolateral thigh (vastus lateralis) in children <3 years; deltoid in older children.
<1 year	All routes	⚠️ Avoid unless under specialist supervision	—	Very limited safety data. Risk of anticholinergic adverse effects (tachycardia, temperature dysregulation, ileus) is higher in infants.

Mandatory Clinical Notes (Paediatric-specific):

When to prefer over alternatives: Consider when a non-sedating antispasmodic is needed in children. The absence of CNS effects is a significant advantage over dicyclomine in children. Mebeverine (available as tablets 135 mg — not easily dose-adjustable for children; suspension not widely available in India) is an alternative for older children (≥12 years typically). Drotaverine is used in some Indian paediatric emergency departments but has limited paediatric-specific data.
When NOT to use:
- ⚠️ Children <6 years (oral tablets) — no appropriate formulation.
- ⚠️ Recurrent abdominal pain in children without adequate evaluation — first rule out organic causes (appendicitis, intussusception, mesenteric lymphadenitis, worm infestation, UTI, constipation, celiac disease) before attributing pain to “functional spasm.”
- ⚠️ Intussusception: Anticholinergics may mask the colicky pain of intussusception and delay diagnosis of this surgical emergency. Maintain a high index of suspicion in children 6 months to 3 years with episodic severe abdominal pain.
NLEM status: Not listed. No paediatric antispasmodic is specifically listed in the NLEM paediatric section.
Time to response: Oral: 15–30 minutes. IV: 1–5 minutes.
Treatment failure: If abdominal pain is recurrent despite antispasmodic therapy, reassess diagnosis. Consider functional abdominal pain disorder management (biopsychosocial approach — dietary modification, stress management, cognitive behavioural therapy, probiotics). Paediatric gastroenterology referral for alarm features (weight loss, bloody stools, nocturnal symptoms, persistent vomiting, family history of IBD).
Baseline investigations: None mandatory for a single episode of typical spasmodic abdominal pain. For recurrent pain: stool examination for ova/parasites (high prevalence of intestinal parasitosis in Indian children), urine routine (rule out UTI), CBC, and abdominal ultrasound. IAP recommends a step-wise diagnostic approach for recurrent abdominal pain.
Specialist initiation: Oral tablets for self-limiting abdominal cramps can be prescribed by a paediatrician in OPD. IV use should be supervised by a paediatrician or emergency physician.
Indian source: IAP Textbook of Pediatrics (current edition) — section on functional abdominal pain and recurrent abdominal pain in children. IAP Guidelines on Functional Gastrointestinal Disorders in Children.
Safety warning: ⚠️ Monitor temperature in febrile children receiving hyoscine butylbromide (parenteral) — anticholinergic suppression of sweating can impair thermoregulation, especially in the Indian hot climate.
Dose adjustment: Reduce IV dose to 0.3 mg/kg in children with hepatic impairment. No adjustment for oral use (negligible absorption).

2. RENAL COLIC — Paediatric (Rare)

Clinical context: Renal colic is uncommon in children but does occur (urolithiasis prevalence is increasing in Indian children, particularly in endemic stone belt regions — Rajasthan, Gujarat, Maharashtra, Punjab, Haryana, Uttar Pradesh). Parenteral hyoscine butylbromide may be used as an adjunct to analgesia.

Dosing — Paediatric (≥1 year):

Route	Dose	Maximum	Notes
IV	0.3–0.5 mg/kg as a single IV bolus	Max 20 mg per dose	Combined with analgesia (paracetamol IV 15 mg/kg or ketorolac 0.5 mg/kg IV in children ≥1 year — use as per paediatric formulary recommendations). Oral route NOT effective for ureteric spasm (negligible systemic absorption).

Evidence basis: Extrapolated from adult data. No paediatric-specific RCTs. Standard practice in Indian paediatric emergency departments.

Indian source: Paediatric urology and emergency department practice at Indian tertiary centres.

Secondary Indications — Paediatric (Off-label)

1. ADJUNCT DURING PAEDIATRIC ENDOSCOPY

OFF-LABEL

Dosing — Paediatric (≥6 years, ≥20 kg):

Route	Dose	Maximum	Notes
IV	0.3–0.5 mg/kg as a single IV bolus at the time of endoscopy	Max 20 mg per dose	Used to reduce bowel spasm during paediatric upper GI endoscopy or colonoscopy. Standard practice at paediatric gastroenterology centres.

Evidence basis: Level of evidence: Weak (extrapolated from adult endoscopy practice; no paediatric-specific RCTs for hyoscine butylbromide as endoscopy adjunct).

No established paediatric dosing below 6 years for endoscopy — use only under specialist (paediatric gastroenterologist) supervision.

MISSED DOSE / DELAYED DOSE GUIDANCE

Context-specific guidance by dosing frequency and clinical use:

1. PRN / Acute Use (acute colic — GI, renal, biliary; single-dose procedural use):

Not applicable — hyoscine butylbromide for acute colic and procedural use is given on an as-needed basis or as a single dose. There is no scheduled dosing to “miss.”

2. Oral Tablets — Regular Dosing (e.g., for IBS, recurrent GI spasm, dysmenorrhoea):

Hyoscine butylbromide oral tablets are most commonly used as PRN therapy (taken when cramps occur), not as a strict scheduled regimen. However, some patients are advised to take regular doses (e.g., 10 mg TDS before meals for IBS symptom control over a defined period).

For three-times-daily (TDS) scheduled dosing:

Scenario	Guidance
Dose delayed by <3 hours	Take the dose as soon as remembered. Resume the regular schedule.
Dose delayed by >3 hours (but next dose not imminent)	Take the dose. Shift subsequent doses to maintain roughly equal spacing.
Dose missed entirely (next scheduled dose is within 2 hours)	Skip the missed dose. Take the next dose at the scheduled time.
⛔ Never double up	Do NOT take two doses at once to compensate for a missed dose.

For twice-daily dosing (if prescribed as such):

Scenario	Guidance
Missed by <4 hours	Take as soon as remembered; resume schedule.
Missed by >4 hours	Skip. Take next dose on time.

3. Continuous SC/IV Infusion in Palliative Care:

Scenario	Guidance
Infusion interrupted <2 hours	Restart at the same rate.
Infusion interrupted >2 hours	Restart at the same rate. A single SC/IV bolus of 20 mg may be given to re-establish effect while restarting the infusion, if secretions have re-accumulated.
Multiple missed bolus doses (>2 missed)	Resume at the same dose. No re-titration needed. Secretions may have re-accumulated — gentle suctioning and repositioning while awaiting drug effect.

4. Prolonged Non-Adherence / Drug Holiday Guidance:

Hyoscine butylbromide is not a drug that carries risk of rebound effects, withdrawal syndrome, or immunogenicity upon discontinuation or resumption.

No risk of rebound — stopping the drug simply allows return of spasm symptoms.
No withdrawal syndrome — can be stopped abruptly at any time.
No re-titration needed — the drug can be resumed at the previous dose after any duration of non-adherence.
Not a biologic — no immunogenicity concern.
Not a narrow therapeutic index drug — no risk of toxicity on resumption at the prior dose.

ℹ️ Patients should be counselled that the drug provides symptom relief only and does not treat the underlying condition. Stopping the drug will lead to recurrence of spasm symptoms if the underlying cause persists.

RECONSTITUTION / ADMINISTRATION QUICK REFERENCE (For Nurses & Clinical Staff)

Reconstitution:

Parameter	Details
Supplied as	Hyoscine butylbromide injection 20 mg/mL in 1 mL glass ampoules. Clear, colourless solution. Ready-to-use — no reconstitution required.
Diluent for further dilution (if needed for paediatric dosing)	Compatible: 0.9% Sodium Chloride (Normal Saline) and 5% Dextrose (D5W).
Incompatible diluents	No specific incompatibilities documented. Avoid mixing with alkaline solutions as a general precaution (quaternary ammonium compounds may be less stable at high pH).
Dilution for paediatric use	Dilute 20 mg (1 mL) in 9 mL of 0.9% NaCl to produce a 2 mg/mL solution. Use a 1 mL syringe for accurate dose measurement in small children. Label clearly with drug name and concentration. Use immediately after dilution; discard unused portion.

Rate of Administration:

Route	Administration Guidance
IV bolus/push	Administer slowly over 1–2 minutes. Rapid IV push may cause a transient drop in blood pressure or a surge of tachycardia. ⚠️ IV hyoscine butylbromide can cause transient hypotension — especially in hypovolaemic patients. Ensure adequate hydration before IV administration.
IM injection	Standard IM injection technique. Inject deep into a large muscle mass: deltoid (adults and children ≥3 years for small volumes ≤1 mL), anterolateral thigh (vastus lateralis) in infants and younger children. Usual volume: 1 mL (20 mg).
SC injection (palliative care)	Inject into subcutaneous tissue of the anterior chest wall, upper arm, anterior thigh, or abdomen. Rotate injection sites. Well tolerated subcutaneously.
SC continuous infusion (syringe driver — palliative care)	Use a portable syringe driver (Graseby MS26 or equivalent). Load the syringe with the required 24-hour dose diluted in an appropriate volume of 0.9% NaCl or Water for Injection (typically 10–20 mL for a standard syringe driver). Insert a 25G or 27G butterfly needle subcutaneously. Secure with transparent dressing. Change insertion site every 72 hours or sooner if inflammation develops at the site.

Weight-Based Dosing Calculation Example (Paediatric — IV):

Example: A 15 kg child presents with acute abdominal colic requiring IV hyoscine butylbromide at 0.5 mg/kg.

- Required dose = 15 × 0.5 = 7.5 mg
- Using the standard 20 mg/mL ampoule:
  - Volume to draw from undiluted ampoule = 7.5 / 20 = 0.375 mL — difficult to measure accurately with a standard syringe.
- Better approach: Dilute to 2 mg/mL (as described above: 1 mL [20 mg] + 9 mL NaCl = 10 mL of 2 mg/mL solution)
  - Volume to draw from diluted solution = 7.5 / 2 = 3.75 mL — much easier to measure accurately.
- Administer as a slow IV bolus over 1–2 minutes.
- Monitor heart rate during and for 15 minutes after administration.

Syringe Driver Compatibility (Palliative Care):

Hyoscine butylbromide is frequently combined with other drugs in a syringe driver for palliative care. Known compatibilities and incompatibilities:

Compatible in Same Syringe Driver	Incompatible — Use Separate Lines
Morphine sulphate	Cyclizine (may precipitate at higher concentrations — check local compatibility charts)
Diamorphine (where available)	Dexamethasone (may precipitate with hyoscine butylbromide at certain concentrations — use a separate syringe/line)
Haloperidol	Phenobarbital (alkaline solution — risk of precipitation)
Midazolam	Diclofenac sodium
Metoclopramide (at standard concentrations)	Ketorolac
Octreotide	—
Levomepromazine	—

⚠️ Always perform a visual compatibility check after mixing. If cloudiness, colour change, or particulate formation is observed, do NOT administer. Prepare drugs in separate syringes with separate infusion sites.

ℹ️ Practical Indian context: Graseby-type syringe drivers may not be available in all palliative care settings in India. In resource-limited settings, intermittent SC bolus dosing every 4–6 hours is an acceptable and practical alternative to continuous infusion.

Stability After Dilution:

Condition	Stability
Undiluted ampoule (unopened)	Store at room temperature (below 30°C). Protect from light. Shelf life as per manufacturer (usually 3–5 years from manufacture).
After opening ampoule (undiluted)	Use immediately. Single-use ampoule — discard any unused portion. No preservative.
Diluted in 0.9% NaCl (for IV use or syringe driver)	Stable for 24 hours at room temperature (25°C) based on general stability principles. Use within 24 hours. Prepare fresh solution daily for continuous infusions.
Diluted to 2 mg/mL (for paediatric use)	Use immediately. No stability data available for this specific dilution. Discard unused portion.

Multi-Dose Vial Handling:

Not applicable — hyoscine butylbromide injection is supplied as single-use 1 mL glass ampoules in India. No multi-dose vials are available.

Y-site / Line Compatibility:

Data limited for hyoscine butylbromide specifically. When administering IV, flush the line with at least 5–10 mL of 0.9% NaCl before and after administration to minimise compatibility concerns with other IV drugs running through the same line.

Special Administration Notes:

Parameter	Details
Filter requirements	No specific in-line filter required for IV administration.
Flush line	Flush IV line with 5–10 mL of 0.9% NaCl before and after IV bolus administration.
Extravasation risk	Low. Not a vesicant. SC administration is routine in palliative care. In the unlikely event of perivenous leakage, observe for local irritation; no specific antidote needed.
IM injection site	Adults: deltoid muscle (for 1 mL volume). Children: anterolateral thigh (vastus lateralis) in children <3 years; deltoid in older children. Avoid gluteal site in children <3 years (risk of sciatic nerve injury).
Oral tablet	Swallow whole with water. Do NOT crush, chew, or split. Film-coated to mask bitter taste. Crushing exposes the bitter drug and there is no stability data for the crushed form. If the patient cannot swallow tablets (children <6 years, dysphagia, NG tube), consider alternative drug (drotaverine available as liquid formulation in some Indian brands) or parenteral route.
Rectal suppository	If available: insert high into the rectum. Retain for at least 30 minutes. Remove foil wrapper completely before insertion. Moisten the tip with water for ease of insertion.
Enteral tube (NG/NJ tube)	NOT suitable for NG tube administration. No liquid formulation exists. Tablets should NOT be crushed for NG tube delivery (no stability/bioavailability data for crushed form in NG tube; film coating may clog narrow-bore tubes). For patients requiring antispasmodic therapy via enteral route, consider alternative drugs with liquid formulations or use parenteral hyoscine butylbromide.

Cold-Chain Drug Guidance:

Not applicable — hyoscine butylbromide injection and tablets are stored at room temperature (below 30°C), protected from light. No cold-chain requirement.

ℹ️ Indian climate note: Store below 30°C. In areas where ambient temperatures regularly exceed 30°C (common across much of India from March to October), store in the coolest available area. Do not store in direct sunlight, in vehicles, or near heat sources. Short-term exposure to temperatures up to 40°C during transport is unlikely to significantly degrade the drug, but prolonged storage above 30°C may reduce shelf life. Suppositories (if available) may soften or melt at temperatures above 30°C — store in a cool place or refrigerator; if softened, refrigerate to re-solidify before use.

Storage Summary:

Formulation	Storage
Injection (unopened ampoule)	Room temperature, below 30°C, protected from light.
Tablets (blister pack)	Room temperature, below 30°C, protected from moisture. Keep in original blister until use.
Suppository (if available)	Below 25°C ideally; may refrigerate. Do not freeze.

RENAL ADJUSTMENT

eGFR formula: No formal renal dosing adjustment guidelines exist for hyoscine butylbromide from CDSCO or standard pharmacological references. The following guidance is based on the drug’s pharmacokinetic profile and clinical principles.

Key pharmacokinetic consideration: When given orally, hyoscine butylbromide has <1% systemic bioavailability — renal impairment is therefore NOT clinically relevant for the oral route, since virtually no drug reaches the systemic circulation. Renal dose adjustment applies ONLY to the parenteral route (IV/IM/SC), where the drug is fully absorbed systemically.

eGFR (mL/min)	Oral Dose Adjustment	Parenteral Dose Adjustment	Notes
>60	No adjustment required.	No adjustment required.	Standard dosing applies for both routes.
30–60	No adjustment required.	No adjustment required. Use standard doses with monitoring.	Monitor for peripheral anticholinergic effects (dry mouth, tachycardia, constipation, urinary retention) — may be slightly prolonged.
15–30	No adjustment required.	Use standard dose but increase dosing interval (e.g., every 8 hours instead of every 6 hours for repeated dosing).	Reduced renal clearance may modestly prolong elimination of the systemically absorbed drug and its metabolites. Monitor for accumulation effects with repeated dosing.
<15 (non-dialysis)	No adjustment required.	⚠️ Use with caution. Use standard single dose for acute colic. For repeated dosing: reduce frequency to every 12 hours or use the lowest effective dose.	Enhanced risk of prolonged anticholinergic effects due to reduced renal clearance of drug and metabolites. If alternative non-anticholinergic antispasmodics are available (drotaverine — primarily hepatic metabolism), consider using those instead.
Haemodialysis	No adjustment required.	Data limited. Significant removal by HD is unlikely (large Vd ~128 L, low protein binding ~4.4%). No supplemental post-dialysis dose is required.	If acute colic occurs around the time of dialysis, standard single dose can be given without timing adjustment relative to HD session.
Peritoneal dialysis	No adjustment required.	Data limited. Not expected to be significantly removed.	Standard dosing with clinical monitoring for anticholinergic effects.
CRRT	No adjustment required.	Data limited. Use standard dosing.	Monitor for prolonged anticholinergic effects in critically ill patients on CRRT.

Augmented Renal Clearance (ARC): Not clinically relevant for hyoscine butylbromide. The drug is not primarily renally cleared as unchanged drug, and its antispasmodic efficacy is not dependent on achieving precise plasma concentrations. No dose increase is required in ARC states.

HEPATIC ADJUSTMENT

Primary clearance pathway: Hepatic hydrolysis (ester bond hydrolysis) is the major route of metabolism for the systemically absorbed fraction of hyoscine butylbromide. No significant CYP450 involvement.

Key pharmacokinetic consideration: As with renal impairment, hepatic impairment is clinically relevant ONLY for the parenteral route. Oral hyoscine butylbromide acts locally in the GI lumen with <1% systemic absorption — hepatic impairment does not meaningfully alter the efficacy or safety of the oral route.

No formal Child-Pugh-based dosing data exists for hyoscine butylbromide.

The following guidance is based on pharmacokinetic principles:

Child-Pugh Class	Oral Dose Adjustment	Parenteral Dose Adjustment	Notes
A (Mild)	No adjustment required.	No formal adjustment required. Use standard doses with clinical monitoring.	Monitor for prolonged anticholinergic effects after parenteral dosing (dry mouth, tachycardia, constipation, urinary hesitancy). In practice, single-dose use for acute colic is unlikely to be significantly affected.
B (Moderate)	No adjustment required.	⚠️ Use with caution. Standard single dose for acute colic is acceptable. For repeated dosing, increase the dosing interval (e.g., every 8–12 hours instead of every 6 hours).	Reduced hepatic hydrolysis capacity may prolong the elimination half-life. Risk of prolonged anticholinergic effects with repeated dosing. The low protein binding (~4.4%) means that hypoalbuminaemia (common in moderate-severe liver disease) does NOT significantly increase free drug fraction — this is reassuring.
C (Severe)	No adjustment required.	⚠️ Use with caution. Single dose for acute colic is acceptable if needed. Avoid repeated or scheduled parenteral dosing if possible.	Markedly reduced hepatic hydrolysis expected. Risk of drug accumulation with repeated doses. Patients with severe liver disease may also have concurrent renal impairment (hepatorenal syndrome), compounding elimination impairment. If an antispasmodic is needed for repeated dosing, consider drotaverine (different metabolic pathway — phosphodiesterase inhibitor, not dependent on ester hydrolysis) or mebeverine (oral, for chronic use).

No formal hepatic dosing data available. Clinical guidance based on pharmacokinetic principles.

Active metabolite accumulation: No clinically significant active metabolites. Inactive metabolites may accumulate in severe hepatic impairment but are not expected to contribute additional pharmacological effects.

Concurrent hepatotoxin note: Hyoscine butylbromide is NOT hepatotoxic — it does not cause drug-induced liver injury. No specific concern regarding additive hepatotoxicity when co-administered with hepatotoxic drugs (rifampicin, isoniazid, pyrazinamide, methotrexate, valproate, antiretrovirals). However, note the following practical interaction:

⚠️ Anticholinergic effects on GI motility in patients with hepatic encephalopathy: In patients with cirrhosis and hepatic encephalopathy, reduced GI motility from anticholinergic drugs can worsen constipation, reduce lactulose efficacy (which depends on osmotic effect and gut transit), and thereby worsen ammonia clearance, potentially precipitating or worsening hepatic encephalopathy. Avoid chronic or repeated anticholinergic use in patients with cirrhosis and hepatic encephalopathy. A single dose for acute colic is acceptable.

Summary — Route-Dependent Adjustment Principle:

ℹ️ This drug has a uniquely split pharmacokinetic profile:

Oral route: No dose adjustment needed in ANY degree of renal or hepatic impairment, because the drug acts locally in the GI lumen and <1% is absorbed systemically.
Parenteral route: Use with increasing caution as organ impairment worsens — primarily because the fully absorbed drug depends on hepatic hydrolysis and renal excretion for clearance. Single doses for acute colic are safe across all impairment levels; repeated or scheduled dosing requires monitoring and dose-interval extension in moderate-to-severe impairment.

CONTRAINDICATIONS

⛔ Absolute contraindications — the drug must NEVER be used in these situations:

Contraindication	Clinical Rationale
⛔ Known hypersensitivity to hyoscine butylbromide or any excipient in the formulation	Risk of anaphylaxis or severe hypersensitivity reaction. Cross-reactivity with hyoscine hydrobromide (scopolamine) is expected — both are tropane alkaloid derivatives. However, cross-reactivity with glycopyrrolate (synthetic quaternary ammonium, structurally unrelated to tropane alkaloids) is NOT expected — glycopyrrolate may be used as an alternative if antispasmodic therapy is essential. Cross-reactivity with atropine is likely (tropane alkaloid structural similarity). Cross-reactivity rate: high among tropane alkaloids (structure-based, predictable); very low between tropane alkaloids and synthetic quaternary ammonium compounds.
⛔ Myasthenia gravis	Anticholinergic agents antagonise the therapeutic effect of acetylcholinesterase inhibitors (pyridostigmine, neostigmine) used to treat myasthenia gravis. Even though oral hyoscine butylbromide has negligible systemic absorption, the parenteral formulation can precipitate worsening of myasthenic weakness, including respiratory muscle weakness that may progress to myasthenic crisis requiring intubation. The oral formulation is also best avoided because even <1% systemic absorption adds anticholinergic load in a patient whose neuromuscular junction is already compromised.
⛔ Untreated narrow-angle (angle-closure) glaucoma	⚠️ This contraindication applies primarily to the PARENTERAL route. Systemically absorbed antimuscarinic drug causes mydriasis (pupil dilation), which pushes the peripheral iris forward and can precipitate acute angle-closure crisis — an ophthalmological emergency that can cause permanent visual loss within hours. For the oral route, the risk is extremely low (due to <1% systemic absorption), but the contraindication is maintained in product inserts for medicolegal completeness. ℹ️ Patients with open-angle glaucoma on adequate treatment are NOT contraindicated — the risk applies specifically to anatomically narrow angles.
⛔ Mechanical gastrointestinal obstruction	Anticholinergic drugs reduce GI motility, which can worsen existing mechanical obstruction, increase intraluminal pressure proximal to the obstruction, and delay diagnosis. The masking of pain can prevent recognition of strangulation or ischaemia. ℹ️ Exception: In inoperable malignant bowel obstruction managed palliatively, hyoscine butylbromide is specifically used to reduce secretions and colic — this is a palliative care indication, not a contraindication in that context (see Secondary Indication in Part 2).
⛔ Paralytic ileus	Anticholinergic drugs further suppress already-absent GI motility, worsening ileus and potentially causing massive intestinal dilation.
⛔ Megacolon (toxic or non-toxic)	Risk of worsening colonic dilation, increased perforation risk, and delayed recognition of peritonitis. Toxic megacolon (e.g., in ulcerative colitis, Clostridioides difficile infection) is a surgical emergency — anticholinergics are absolutely contraindicated.
⛔ Urinary retention due to complete obstructive uropathy	Anticholinergic blockade of the detrusor muscle worsens urinary retention. In patients with complete urinary outlet obstruction (e.g., large prostatic enlargement, urethral stricture, pelvic mass causing bilateral ureteric obstruction), hyoscine butylbromide can precipitate acute urinary retention requiring emergency catheterisation. ℹ️ Patients with mild-to-moderate prostatic symptoms (incomplete obstruction) are listed under Cautions, not here.
⛔ Tachyarrhythmia — uncontrolled	The vagolytic (anticholinergic) effect of systemically absorbed hyoscine butylbromide increases heart rate. In patients with uncontrolled atrial fibrillation with rapid ventricular response, SVT, or VT, additional heart rate acceleration can precipitate haemodynamic instability. ℹ️ This contraindication applies primarily to the parenteral route. Oral route risk is minimal due to negligible absorption.

Allergy Cross-Reactivity Summary:

Drug/Class	Cross-Reactivity with Hyoscine Butylbromide	Approximate Rate	Nature
Hyoscine hydrobromide (scopolamine)	YES — high	Very high (parent compound is scopolamine; butylbromide is a quaternary derivative)	Structure-based (predictable)
Atropine	YES — moderate-high	High (both tropane alkaloids)	Structure-based (predictable)
Hyoscyamine	YES — high	High (tropane alkaloid)	Structure-based
Homatropine	YES — moderate	Moderate-high (semi-synthetic tropane)	Structure-based
Tropicamide	LOW	Low (<5%)	Different chemical class (synthetic, non-tropane)
Glycopyrrolate	NONE expected	Nil — structurally unrelated (synthetic quaternary ammonium, non-tropane)	Safe alternative in tropane alkaloid allergy
Dicyclomine	LOW-MODERATE	Low-moderate (tertiary amine, not a tropane alkaloid; different chemical backbone)	Idiosyncratic — cannot fully predict
Ipratropium, tiotropium	LOW	Very low — different quaternary ammonium structures (though tiotropium is structurally related to scopolamine quaternary derivative)	Tiotropium: theoretical risk — structure more closely related than ipratropium. Clinical cross-reactivity not documented.
Mebeverine, drotaverine, papaverine	NONE	Nil — completely different chemical classes (non-anticholinergic smooth muscle relaxants)	Safe alternatives — no structural or mechanistic overlap

CAUTIONS

⚠️ HIGH-PRIORITY CAUTIONS (serious harm possible without active monitoring or dose adjustment):

Condition	Risk	Required Monitoring / Action
⚠️ Prostatic hypertrophy (BPH) without complete obstruction	Increased risk of acute urinary retention, especially after parenteral administration. Even oral tablets carry a small risk in patients with significant prostatic enlargement (though systemic absorption is <1%, the local effect on bladder/urethral smooth muscle during gut transit may contribute theoretically).	Enquire about urinary symptoms (IPSS score if possible) before prescribing. After parenteral dose: monitor urine output for at least 4–6 hours. Ensure catheterisation is available. Advise the patient to report inability to void. Consider drotaverine or mebeverine as alternatives with no antimuscarinic mechanism.
⚠️ Cardiac conditions — ischaemic heart disease, heart failure, compensated arrhythmias	Parenteral route only. Tachycardia from anticholinergic effect increases myocardial oxygen demand. In coronary artery disease, this can provoke angina or ischaemia. In heart failure, tachycardia reduces diastolic filling time and worsens cardiac output.	Monitor heart rate and ECG during and for 15–30 minutes after IV administration. Avoid in unstable angina or decompensated heart failure. A single dose for acute colic in stable coronary disease is usually tolerable with monitoring. Oral tablets are safe (negligible systemic absorption).
⚠️ Hyperthyroidism	Patients with hyperthyroidism have increased sensitivity to tachycardia-inducing effects of anticholinergics. The baseline elevated sympathetic tone and tachycardia of thyrotoxicosis can be dangerously compounded by anticholinergic vagolysis after parenteral dosing.	Use oral route preferentially (negligible systemic effect). If IV is needed for acute colic, use standard dose with continuous heart rate monitoring. Have short-acting beta-blocker available for rescue if tachycardia becomes haemodynamically significant.
⚠️ Autonomic neuropathy (e.g., diabetic)	Exaggerated peripheral anticholinergic response — excessive tachycardia, postural hypotension, gastroparesis worsening, urinary retention. Autonomic neuropathy alters baseline parasympathetic tone, making the effects of muscarinic blockade unpredictable. Relevant primarily to parenteral route.	Reduce parenteral dose if possible (0.5 mg/kg instead of standard 20 mg fixed dose). Monitor heart rate and blood pressure (lying and standing) for at least 30 minutes after parenteral administration. Oral route is safe.
⚠️ Elderly patients (≥60 years) — parenteral route	Although hyoscine butylbromide does NOT cross the BBB (no delirium risk), elderly patients are more susceptible to peripheral anticholinergic effects: tachycardia (may be poorly tolerated with reduced cardiac reserve), urinary retention (high prevalence of BPH in Indian males ≥60 years), constipation (worsened immobility-related constipation), and dry mouth (impairs denture comfort and oral hygiene).	See dedicated ELDERLY section for full guidance. Use standard parenteral dose for acute colic (single dose is safe). For repeated parenteral dosing, increase dosing interval. Oral tablets are well tolerated in elderly (negligible systemic absorption).
⚠️ Patients on other anticholinergic drugs	Additive peripheral anticholinergic burden — tachycardia, constipation, urinary retention, dry mouth, hyperthermia, ileus. This risk applies to parenteral hyoscine butylbromide. The oral route adds minimal systemic anticholinergic burden (<1% absorption). Common co-prescribed anticholinergics in Indian practice: dicyclomine, oxybutynin, tolterodine, chlorpheniramine, amitriptyline, hydroxyzine, promethazine, trihexyphenidyl, atropine.	Review the patient’s medication list for existing anticholinergics before prescribing parenteral hyoscine butylbromide. If total anticholinergic burden is already high, consider non-anticholinergic alternatives (drotaverine, mebeverine).
⚠️ Hypovolaemia / dehydration	⚠️ IV hyoscine butylbromide can cause transient hypotension, particularly in dehydrated patients. The mechanism involves peripheral vasodilation from muscarinic blockade on vascular smooth muscle. This is a well-documented but often overlooked caution.	Ensure adequate hydration before IV administration. Monitor blood pressure during and for 15 minutes after IV bolus. If hypotension occurs, it is usually transient and responds to IV fluid bolus. In severely dehydrated patients (e.g., acute gastroenteritis with dehydration presenting with abdominal cramps), rehydrate FIRST, then administer antispasmodic if still needed.
⚠️ Pyrexia (fever) or high ambient temperature	Parenteral route only. Systemically absorbed anticholinergic drug suppresses sweating, impairing thermoregulation. In febrile patients or in hot environmental conditions (common across India for most of the year), this can contribute to hyperthermia, particularly in children, elderly, and those with limited access to cooling.	Monitor temperature after parenteral administration. Ensure the patient is in a cooled environment. Provide external cooling if needed. Oral tablets are safe (no systemic anticholinergic effect).
⚠️ Gastro-oesophageal reflux disease (GORD)	Anticholinergics reduce lower oesophageal sphincter (LOS) tone, worsening gastro-oesophageal reflux. Relevant primarily to parenteral route. Oral hyoscine butylbromide may have minor local effect on the LOS during passage through the oesophago-gastric junction, but this is usually clinically insignificant.	Consider alternatives (drotaverine, mebeverine) in patients with significant GORD symptoms. If hyoscine butylbromide is needed, advise upright posture for 30 minutes after oral dosing and co-prescribe a PPI if GORD is symptomatic.

STANDARD CAUTIONS (conditions needing awareness but carrying lower risk):

Condition	Notes
Down syndrome	Increased sensitivity to anticholinergic agents — exaggerated tachycardia and temperature dysregulation. Relevant to parenteral route. Oral route is safe. Use lower parenteral dose (0.3 mg/kg).
Ulcerative colitis (active, non-megacolon)	Risk of reduced GI motility worsening colitis or precipitating toxic dilation. Use with caution; monitor bowel function. Contraindicated only if toxic megacolon is present or suspected (see Contraindications).
Chronic constipation	Anticholinergic effect may worsen constipation. Relevant primarily to repeated oral dosing or parenteral use. A single oral dose for acute cramps is unlikely to be significant. Advise adequate fluid intake and fibre.
Hiatus hernia with reflux	Reduced LOS tone may worsen reflux symptoms. Minor concern with oral route.
Epilepsy	Data limited. Theoretical concern about seizure threshold lowering at very high doses or in overdose. Not a significant clinical concern at standard therapeutic doses. Hyoscine butylbromide does NOT cross the BBB, so direct central seizure threshold effects are not expected.
Contact lens wearers	Anticholinergic-induced reduction in tear production (systemic route) may cause dry eye discomfort with contact lenses. Minimal concern with oral route.
Patients performing tasks requiring alertness	ℹ️ Oral hyoscine butylbromide does NOT cause drowsiness (does not cross the BBB). Patients CAN drive, operate machinery, and perform cognitive tasks while on oral hyoscine butylbromide. This is a major advantage over dicyclomine, promethazine, and hyoscine hydrobromide, which all cause sedation. After IV administration, transient dizziness or light-headedness may occur due to hypotension — advise against driving for 2 hours after IV dose.
Renal impairment (mild-moderate)	See RENAL ADJUSTMENT section. Oral route: no concern. Parenteral route: monitor for prolonged effects with repeated dosing.
Hepatic impairment (mild-moderate)	See HEPATIC ADJUSTMENT section. Same principle as renal impairment — route-dependent concern.
Patients with hepatic encephalopathy	⚠️ Anticholinergic-induced constipation may worsen ammonia clearance and precipitate hepatic encephalopathy. Avoid repeated or chronic anticholinergic use in cirrhosis with encephalopathy. Single dose for acute colic is acceptable. See HEPATIC ADJUSTMENT for details.

PREGNANCY

Parameter	Details
Overall safety statement	⚠️ Use with caution — limited human safety data. Hyoscine butylbromide has been used extensively in Indian obstetric practice (for cervical dilation and for colic during pregnancy), but formal safety data from prospective studies or pregnancy registries is limited. Animal reproductive toxicity studies reported in the product insert have not shown teratogenicity at recommended doses, but animal studies are not always predictive of human risk. (Former US-FDA category was not formally assigned for this drug; some references classify it as pregnancy category B based on animal data, but this classification system is no longer used as primary guidance.)
Teratogenicity window	No specific teratogenic window has been identified. No consistent pattern of structural malformations has been reported in human post-marketing surveillance despite decades of widespread global use (including extensive Indian use). The general period of highest vulnerability for any drug-induced organogenesis defects is weeks 3–8 post-conception (weeks 5–10 of gestational age) — non-essential drug use should be avoided during this period as a general principle.
First trimester	Avoid non-essential use during the first trimester as a precautionary measure (limited formal human teratogenicity data). If needed for acute colic (e.g., renal colic, biliary colic during early pregnancy), the parenteral route can be used for acute relief with appropriate risk-benefit assessment.
Second trimester	Considered the safest window for use if clinically needed. Oral tablets for GI spasm can be used for short courses. Parenteral use for acute colic is acceptable.
Third trimester and peripartum	Widely used in Indian obstetric practice (off-label) for cervical dilation during labour — see Secondary Indication 1 in Part 2. The quaternary ammonium structure limits placental transfer. ⚠️ Maternal tachycardia — monitor heart rate after parenteral administration. ⚠️ Fetal tachycardia: Less likely with hyoscine butylbromide than with hyoscine hydrobromide (due to limited placental transfer of quaternary ammonium compounds), but transient fetal tachycardia has been reported — monitor FHR with CTG.
Preferred alternatives in Indian obstetric practice	For GI spasm during pregnancy: drotaverine (widely used in Indian obstetric practice; considered safe; not an antimuscarinic — PDE-4 inhibitor mechanism). For pain relief: paracetamol (safe throughout pregnancy). For IBS-related spasm: mebeverine (direct smooth muscle relaxant; no antimuscarinic effects; limited human pregnancy data but no reported teratogenicity).
What to monitor (mother)	Heart rate (tachycardia after parenteral dose), blood pressure (hypotension risk with IV), urinary output.
What to monitor (fetus)	CTG monitoring during and after parenteral administration in the third trimester or during labour. Anticipate transient fetal tachycardia — interpret CTG in this context.
Pre-conception counselling	No specific pre-conception washout or supplementation required. The drug is not used chronically in the pre-conception period.
Contraception requirement	No mandatory contraception during treatment. The drug is not known to be teratogenic.

Pregnancy Prevention Programme / Registry:

Not applicable — hyoscine butylbromide does not have a mandatory pregnancy prevention programme or pregnancy exposure registry.

Fertility Effects:

No known significant effect on male or female fertility at therapeutic doses. The quaternary ammonium structure and negligible systemic absorption from oral dosing make fertility effects extremely unlikely. No specific washout period before planned conception is required.

LACTATION

Parameter	Details
Compatibility with breastfeeding	Compatible — low risk. Hyoscine butylbromide is considered compatible with breastfeeding based on its pharmacokinetic profile. The drug is a quaternary ammonium compound with low molecular weight lipophilicity — quaternary ammonium compounds are poorly absorbed from the GI tract. Even if small amounts enter breast milk, the infant would absorb negligible amounts from the GI tract (the infant’s gut handles it the same way as the mother’s gut — <1% absorption). Additionally, oral maternal dosing results in <1% systemic availability in the mother, further minimising drug exposure to the infant via milk.
Drug levels in milk	Data limited. Qualitatively: expected to be very low to negligible. No formal RID (Relative Infant Dose) has been established. Based on pharmacokinetic principles (quaternary ammonium structure, poor lipid solubility, low oral bioavailability in both mother and infant), infant exposure through breast milk is estimated to be clinically insignificant.
What to monitor in infant	Routine monitoring only. Watch for: any reduction in feeding (unlikely), excessive fussiness (unlikely), constipation (theoretical — very unlikely given negligible exposure), or tachycardia (extremely unlikely). In practice, no specific monitoring beyond routine infant assessment is needed.
Preferred alternatives during lactation	If additional reassurance is desired: drotaverine (non-anticholinergic; considered compatible with breastfeeding), mebeverine (non-anticholinergic; limited lactation data but no reported adverse effects), paracetamol (safe analgesic during lactation).
Timing advice	Not required — the drug is considered compatible with breastfeeding without timing restrictions. No need to time doses around feeds.

Effect on milk production:

No known effect on milk production. Unlike atropine and hyoscine hydrobromide (which can theoretically suppress milk production through central and peripheral anticholinergic effects on the mammary gland), hyoscine butylbromide has negligible systemic absorption from oral dosing and does not cross the BBB. Peripheral antimuscarinic effects on mammary gland secretion from the <1% systemically absorbed oral fraction are clinically insignificant. After parenteral dosing, a transient reduction in secretory gland output is theoretically possible, but no clinical reports of lactation suppression from hyoscine butylbromide exist.

Temporary incompatibility guidance:

Not applicable — the drug is compatible with breastfeeding. No need to withhold breastfeeding, pump and discard, or time doses around feeds.

ELDERLY

Definition: ≥60 years (consistent with Indian Census and National Programme for Health Care of the Elderly).

ℹ️ Hyoscine butylbromide has a MORE FAVOURABLE safety profile in the elderly compared to tertiary amine antimuscarinics (atropine, hyoscine hydrobromide, dicyclomine). The key advantage is that it does NOT cross the blood-brain barrier — therefore it does NOT cause:

Delirium / acute confusion
Cognitive impairment
Sedation / drowsiness
Hallucinations
Falls from CNS depression

These are the most dangerous anticholinergic effects in elderly patients and are the primary reason why drugs like atropine, hyoscine hydrobromide, dicyclomine, and tricyclic antidepressants are flagged on Beers Criteria and STOPP lists.

However, hyoscine butylbromide DOES exert peripheral anticholinergic effects (tachycardia, urinary retention, constipation, dry mouth) — and elderly patients are more susceptible to these. The risk is highest with the parenteral route (full systemic absorption) and lowest with the oral route (<1% absorption).

Parameter	Details
Recommended starting dose — Oral	10 mg three times daily — same as younger adults. No dose reduction needed for the oral route because systemic absorption is negligible. The drug acts locally in the GI lumen.
Recommended starting dose — Parenteral (IV/IM)	20 mg as a single dose for acute colic — same as younger adults. A single dose is well tolerated. For repeated parenteral dosing, consider increasing the dosing interval to every 8–12 hours (instead of every 6 hours) to reduce cumulative peripheral anticholinergic exposure.
Titration	Oral: may increase to 20 mg per dose TDS if 10 mg is insufficient (same as adults). Parenteral: no titration — fixed dose per event.
Key risks in elderly	1. Urinary retention — the most important practical risk. High prevalence of BPH in Indian males ≥60 years. After parenteral dose, ensure the patient voids within 4–6 hours. Have catheterisation available. 2. Constipation — may worsen existing age-related constipation, especially in immobile patients or those on opioids. 3. Tachycardia — may be poorly tolerated in elderly patients with ischaemic heart disease, aortic stenosis, or diastolic dysfunction. Monitor heart rate after parenteral dose. 4. Dry mouth — worsens denture comfort, oral hygiene, and swallowing. Can compound existing xerostomia from other medications (antihypertensives, antidepressants, diuretics). 5. Hypotension — IV hyoscine butylbromide can cause transient hypotension, which is more significant in elderly patients on antihypertensives or with orthostatic hypotension. Monitor blood pressure. 6. Heat-related illness — anticholinergic suppression of sweating (parenteral route) in elderly patients with impaired thermoregulation + Indian hot climate → risk of heat-related illness. Ensure cooling measures.

Anticholinergic Cognitive Burden (ACB):

ℹ️ Hyoscine butylbromide has a unique position in the ACB classification:

ACB Score: 1 (possible anticholinergic activity) — this is the lowest score for an antimuscarinic drug.
The low ACB score reflects the fact that the drug does NOT cross the blood-brain barrier and therefore does NOT exert central anticholinergic effects (which are the primary driver of cognitive impairment in elderly patients).
For comparison:
- Hyoscine hydrobromide: ACB 3 (definite, high cognitive effect)
- Dicyclomine: ACB 3
- Atropine: ACB 3
- Oxybutynin: ACB 3
- Amitriptyline: ACB 3
- Chlorpheniramine: ACB 3
- Hyoscine butylbromide: ACB 1

💡 Clinical implication: When an elderly patient needs an antispasmodic and the prescriber wants to minimise anticholinergic cognitive burden, hyoscine butylbromide (oral) is the preferred antimuscarinic option among available anticholinergic antispasmodics. Non-anticholinergic alternatives (mebeverine, drotaverine) have zero anticholinergic burden but different mechanisms of action.

Cumulative burden assessment: Even though hyoscine butylbromide’s individual ACB is low, always review the full medication list for other anticholinergic drugs. In elderly Indian patients, common offenders include amitriptyline (widely prescribed for neuropathic pain and depression), chlorpheniramine (OTC antihistamine), hydroxyzine (anxiety/pruritus), oxybutynin (overactive bladder), and ranitidine (though ranitidine has been withdrawn in many markets, H₂ receptor antagonists have mild anticholinergic properties).

Beers Criteria / STOPP-START Relevance:

Criteria	Recommendation
American Geriatrics Society Beers Criteria (2023)	Hyoscine butylbromide is NOT specifically listed in the Beers Criteria as a drug to avoid in older adults. The Beers Criteria lists “scopolamine (hyoscine)” as avoid — but this refers to hyoscine hydrobromide (which crosses the BBB and causes delirium). Hyoscine butylbromide, which does NOT cross the BBB, is pharmacologically distinct and does not carry the same central anticholinergic risk. However, Beers does recommend avoiding all “strongly anticholinergic drugs” — hyoscine butylbromide has only weak systemic anticholinergic activity (ACB 1) from oral dosing.
STOPP Criteria (v2)	STOPP D1 (antimuscarinic drugs in patients with dementia) would apply ONLY if the drug had central anticholinergic effects — hyoscine butylbromide does not. However, STOPP K1 (antimuscarinic drugs with other anticholinergics) applies to the additive peripheral burden from parenteral use.

ℹ️ These criteria are referenced as additional international guidance, not as primary Indian guidance.

Common clinical scenarios in elderly Indian patients:

Scenario	Guidance
Elderly patient with abdominal cramps + BPH	Oral hyoscine butylbromide 10 mg TDS is acceptable (negligible systemic absorption → minimal urinary retention risk). If parenteral dose is needed, monitor urine output for 6 hours after dose. Consider drotaverine (non-anticholinergic) as an alternative if BPH is significant.
Elderly patient with IBS + polypharmacy (on amitriptyline + chlorpheniramine)	Total ACB from existing medications is already ≥4 (amitriptyline 3 + chlorpheniramine 3 = 6). Adding oral hyoscine butylbromide (+1) is acceptable because oral ACB contribution is minimal. However, review whether amitriptyline and chlorpheniramine can be replaced with less anticholinergic alternatives (nortriptyline → lower ACB; cetirizine/fexofenadine → non-sedating, lower ACB). Consider mebeverine instead of hyoscine butylbromide for IBS (zero anticholinergic burden).
Elderly patient with acute renal colic requiring IV antispasmodic	IV hyoscine butylbromide 20 mg is acceptable as a single dose with cardiac monitoring. Monitor heart rate, blood pressure, and urinary output. If patient has significant cardiac history (recent MI, decompensated HF), prefer IV drotaverine (no anticholinergic cardiac effects).
Elderly patient with constipation-predominant symptoms	⚠️ Avoid hyoscine butylbromide (antimotility effect worsens constipation). Prefer mebeverine or drotaverine. If antispasmodic is needed for acute cramps, limit to single doses with concurrent laxative therapy.

Deprescribing Guidance:

Parameter	Details
When to consider stopping	If hyoscine butylbromide has been prescribed regularly for IBS or recurrent abdominal spasm and the patient’s symptoms have improved or stabilised, consider a trial of discontinuation. If the patient has been taking it for >4 weeks regularly, reassess whether the underlying condition still warrants antispasmodic therapy.
Tapering schedule	Not required — hyoscine butylbromide can be stopped abruptly at any time. There is no withdrawal syndrome, no rebound effect, no drug dependence. Simply discontinue.
Expected withdrawal effects	None. Stopping the drug may lead to recurrence of spasm symptoms if the underlying cause persists, but this is not a drug withdrawal effect — it is return of the untreated condition.

MAJOR DRUG INTERACTIONS

⛔ Interactions that are contraindicated, can cause life-threatening adverse events, or require mandatory dose adjustment / alternative drug selection.

ℹ️ Important note on route-dependence of interactions: Because oral hyoscine butylbromide has <1% systemic bioavailability, most drug-drug interactions listed below are clinically relevant ONLY for the parenteral route (where full systemic absorption occurs). For the oral route, the systemic drug-drug interaction risk is minimal. However, local GI interactions (e.g., effects on GI motility altering absorption of co-administered oral drugs) apply to both oral and parenteral routes. This distinction is noted for each interaction below.

Interacting Drug/Substance	Mechanism	Clinical Effect	Onset Type	Route Relevance	Action Required
⛔ Other anticholinergic drugs (additive): Atropine, hyoscine hydrobromide, dicyclomine, oxybutynin, tolterodine, solifenacin, trihexyphenidyl, benztropine, orphenadrine, amitriptyline (and other TCAs), chlorpheniramine, hydroxyzine, promethazine, chlorpromazine, clozapine, olanzapine	Additive peripheral muscarinic receptor blockade	⚠️ Additive peripheral anticholinergic toxicity: tachycardia, severe constipation → ileus, urinary retention, hyperthermia (impaired sweating), dry mouth, blurred vision. Unlike hyoscine hydrobromide, hyoscine butylbromide does NOT add central (CNS) anticholinergic burden — so delirium and cognitive impairment are NOT expected from this specific drug. However, if the co-administered drug ITSELF has central anticholinergic effects (e.g., amitriptyline, chlorpheniramine), those central effects are NOT opposed or mitigated by hyoscine butylbromide.	Acute onset (peripheral effects within hours of co-administration)	Parenteral route: HIGH risk. Oral route: minimal risk (negligible systemic absorption of hyoscine butylbromide).	⚠️ Review medication list. Avoid combining parenteral hyoscine butylbromide with other strong anticholinergics if possible. If unavoidable, use the lowest dose of each and monitor heart rate, bowel function, urinary output, and temperature. For oral hyoscine butylbromide: combination is generally safe due to minimal systemic contribution, but be aware of additive effects on GI motility (both drugs slow gut transit when given orally).
⚠️ Potassium chloride oral solid preparations (sustained-release/enteric-coated KCl tablets)	Anticholinergic-induced reduction in GI motility prolongs contact of the solid KCl formulation with the GI mucosa	⚠️ Risk of GI ulceration, stricture, and small bowel perforation. This interaction applies to ORAL hyoscine butylbromide as well, because the local antimotility effect in the gut (which is the drug’s intended therapeutic action) slows transit of the solid KCl dosage form.	Gradual onset — mucosal damage occurs over days of concurrent use	Both oral and parenteral routes	⛔ Avoid concurrent use of solid oral KCl formulations with hyoscine butylbromide (any route). If potassium supplementation is needed, use liquid KCl preparations or IV potassium.
⚠️ Cholinesterase inhibitors (donepezil, rivastigmine, galantamine, pyridostigmine, neostigmine)	Pharmacodynamic antagonism — hyoscine butylbromide blocks the muscarinic receptors that cholinesterase inhibitors activate by increasing ACh	⚠️ Reduced efficacy of cholinesterase inhibitors. In Alzheimer’s dementia patients on donepezil/rivastigmine: potential for worsened cognition (though hyoscine butylbromide’s effect is peripheral — the practical clinical impact on cognition is uncertain). In myasthenia gravis patients: contraindicated — see Contraindications.	Acute onset (pharmacodynamic antagonism is immediate)	Parenteral route: significant. Oral route: uncertain clinical impact (peripheral antagonism only).	⛔ Contraindicated in myasthenia gravis. In dementia patients on cholinesterase inhibitors: oral hyoscine butylbromide is likely acceptable for short-term GI spasm relief (peripheral effect only, does NOT affect central cholinergic activity). Parenteral use: avoid if possible; use drotaverine or mebeverine instead.
⚠️ Metoclopramide / domperidone — when used specifically for gastroparesis or gastric emptying	Pharmacodynamic antagonism at the GI level — hyoscine butylbromide reduces GI motility while metoclopramide/domperidone increase it	⚠️ Reduced prokinetic efficacy. If the clinical goal is to promote gastric emptying (e.g., diabetic gastroparesis, post-surgical ileus recovery), adding an antimotility anticholinergic directly opposes this goal. The antiemetic effect (via CTZ antagonism for metoclopramide, or peripheral D₂ blockade for domperidone) may be partially preserved.	Acute onset	Both oral and parenteral routes (oral hyoscine butylbromide reduces GI motility locally)	⚠️ Do NOT co-prescribe when the clinical goal is gastric emptying acceleration. If the patient needs an antiemetic AND an antispasmodic, use ondansetron for antiemesis (5-HT₃ antagonist — no prokinetic effect to oppose) and hyoscine butylbromide for spasm.

Food-Drug and Herb-Drug Interactions (Major):

Substance	Mechanism	Clinical Effect	Route Relevance	Action
Alcohol (ethanol)	ℹ️ Unlike hyoscine hydrobromide or dicyclomine, hyoscine butylbromide does NOT cause CNS depression (does not cross BBB). Therefore, the usual “avoid alcohol — additive sedation” warning does NOT apply. However, alcohol increases gastric acid secretion and may worsen the underlying GI symptoms that hyoscine butylbromide is being prescribed for.	No additive CNS depression. May reduce clinical efficacy for GI symptoms.	Both routes	ℹ️ No pharmacological interaction. Advise moderate alcohol restriction as part of GI symptom management, not because of drug interaction per se.

No major food-drug or herb-drug interactions specific to hyoscine butylbromide are documented. The drug is not metabolised by CYP450 enzymes and does not have known interactions with grapefruit, dairy, or traditional Indian herbal medicines.

MODERATE DRUG INTERACTIONS

Interactions that usually can be managed with monitoring or minor dose adjustment.

Interacting Drug/Substance	Mechanism	Clinical Effect	Onset Type	Route Relevance	Action Required
Drugs with absorption affected by GI transit time — oral formulations of: Digoxin, levodopa, iron supplements, tetracyclines, bisphosphonates, mycophenolate, tacrolimus	Hyoscine butylbromide (oral or parenteral) reduces GI motility, increasing GI transit time. This can alter the absorption profile of co-administered oral drugs — potentially increasing absorption of slowly-dissolving drugs (e.g., digoxin tablets, slow-release formulations) or delaying absorption of time-sensitive drugs (e.g., levodopa).	Variable: May increase absorption of some drugs (digoxin — risk of toxicity), delay absorption of others (levodopa — delayed onset of motor benefit), or have minimal clinical effect depending on the specific drug’s absorption characteristics.	Gradual onset	Both oral and parenteral routes (both reduce GI motility)	ℹ️ For most co-administered oral drugs, no dose adjustment is needed with short-term hyoscine butylbromide use. For digoxin: monitor for toxicity (nausea, visual changes, bradycardia) if hyoscine butylbromide is used concurrently for >3 days. Check digoxin levels if clinically concerned. For levodopa: Time hyoscine butylbromide dose at least 2 hours away from levodopa. For narrow therapeutic index drugs on oral administration: be aware of potential altered absorption.
Beta-adrenergic agonists (salbutamol, terbutaline)	Both beta-agonists and anticholinergics increase heart rate via different mechanisms (beta-agonist → direct chronotropy; anticholinergic → vagolysis). Additive tachycardia risk.	⚠️ Additive tachycardia — usually mild and transient. More significant in patients with pre-existing cardiac conditions.	Acute onset	Parenteral route primarily (oral hyoscine butylbromide contributes negligible systemic anticholinergic effect).	Monitor heart rate. Usually clinically insignificant with standard doses of each. Relevant in acute asthma management where nebulised salbutamol and IV hyoscine butylbromide (for concurrent abdominal colic) may be co-administered — tachycardia may be marked.
Dopamine antagonist antiemetics (metoclopramide, domperidone) — when used for antiemesis only	Pharmacodynamic: opposite effects on GI motility (see Major Interactions). However, the antiemetic action of metoclopramide/domperidone (via CTZ and peripheral D₂ blockade) is at least partially preserved even when GI motility effects are opposed.	Reduced prokinetic effect but partial preservation of antiemetic effect.	Acute onset	Both routes	ℹ️ If the clinical goal is antiemesis only (not gastric emptying), the combination is acceptable with awareness that the prokinetic benefit is lost. Consider using ondansetron instead of metoclopramide/domperidone if both antiemesis and antispasmodic therapy are needed concurrently. Ondansetron does not affect GI motility and does not interact with hyoscine butylbromide.
Sublingual nitrates (GTN/ISDN)	Anticholinergic-induced dry mouth (from parenteral route) reduces sublingual tablet dissolution, potentially delaying or reducing GTN absorption.	⚠️ Reduced bioavailability of sublingual GTN — clinically relevant only after parenteral hyoscine butylbromide (which causes systemic dry mouth). Oral hyoscine butylbromide causes minimal dry mouth (negligible systemic absorption).	Acute onset	Parenteral route only	ℹ️ If the patient needs sublingual GTN after receiving parenteral hyoscine butylbromide, advise sipping a small amount of water to moisten the mouth before placing the GTN tablet sublingually. Alternatively, use GTN spray (buccal absorption — not dependent on saliva). Adjust GTN formulation to spray if concurrent parenteral anticholinergic use is anticipated.
Antacids (aluminium/magnesium hydroxide)	Potential alteration of GI pH and transit time affecting hyoscine butylbromide dissolution and local exposure in the GI lumen.	Clinical significance uncertain. Theoretical reduction in local efficacy if antacid alters GI environment.	Gradual onset	Oral route	ℹ️ Separate administration by at least 1 hour. Give hyoscine butylbromide first, then antacid after 1 hour. Unlikely to be clinically significant for most patients.
Antidiarrhoeals (loperamide)	Additive reduction in GI motility. Loperamide acts via opioid receptors on gut smooth muscle; hyoscine butylbromide via muscarinic receptor blockade.	⚠️ Additive antimotility effect — risk of excessive constipation, abdominal distension, or ileus (especially in elderly, postoperative patients, or those on opioids).	Gradual onset	Both routes	⚠️ Avoid concurrent use unless specifically intended (e.g., severe IBS-D where both mechanisms are needed). If used together, monitor bowel function closely. In Indian practice, loperamide + hyoscine butylbromide may be co-prescribed for severe diarrhoea with cramps — acceptable for short courses (1–2 days) with monitoring.
Topiramate	Additive reduction in sweating — topiramate (carbonic anhydrase inhibitor) + anticholinergic (suppresses sweating) = synergistic impairment of thermoregulation.	⚠️ Oligohidrosis and hyperthermia risk — especially in children and in hot Indian climate.	Gradual onset	Parenteral route primarily; oral route: minimal concern	⚠️ Avoid prolonged concurrent use with parenteral hyoscine butylbromide. Short-term use (single dose for acute colic) is acceptable. Monitor temperature.
Corticosteroids (systemic)	Both drugs can increase intraocular pressure — corticosteroids via posterior subcapsular mechanism; hyoscine butylbromide via mydriasis (parenteral route) and aqueous outflow obstruction in predisposed eyes.	Additive risk of raised IOP in patients with pre-existing narrow angles or steroid-induced glaucoma.	Gradual onset	Parenteral route	Monitor IOP in patients receiving both drugs, especially those with glaucoma risk factors. Single parenteral dose is unlikely to cause clinically significant IOP change.

Herb-Drug and Traditional Medicine Interactions (Moderate):

Substance	Mechanism	Clinical Effect	Action
Datura stramonium (dhatura)	Contains tropane alkaloids (atropine, scopolamine, hyoscyamine) — additive anticholinergic effect with any antimuscarinic drug, including hyoscine butylbromide	⚠️ Additive peripheral anticholinergic toxicity (tachycardia, urinary retention, constipation, hyperthermia, dry mouth). CNS toxicity from dhatura itself (hallucinations, delirium) will NOT be mitigated by hyoscine butylbromide (which does not cross the BBB). Traditional medicine interaction.	⛔ Ask about dhatura use (used as folk remedy/intoxicant in some Indian regions). Avoid concurrent use.
Belladonna-containing Ayurvedic or Unani preparations	Same as above — contain tropane alkaloids	Additive peripheral anticholinergic effects. Traditional medicine interaction.	⛔ Enquire about use. Avoid.
Isabgol (psyllium husk — Plantago ovata)	Isabgol is a bulk-forming laxative that increases GI transit. Hyoscine butylbromide reduces GI transit. Pharmacodynamic opposition.	Reduced efficacy of isabgol (constipation may not improve as expected). Also: hyoscine butylbromide tablet may interact with isabgol gel matrix in the GI lumen, potentially altering local drug exposure.	ℹ️ Separate oral doses by at least 2 hours. Clinical significance is uncertain but separation is prudent.
Triphala (Ayurvedic preparation)	Triphala has mild prokinetic/laxative properties. Pharmacodynamic opposition with anticholinergic antimotility effect.	Reduced laxative/prokinetic effect of Triphala.	ℹ️ Minor interaction. Separate doses. Clinical significance is low.

COMMON ADVERSE EFFECTS

ℹ️ The adverse-effect profile of hyoscine butylbromide is dominated by peripheral antimuscarinic pharmacology. Because the drug does NOT cross the blood-brain barrier (quaternary ammonium compound), central nervous system adverse effects (sedation, drowsiness, confusion, delirium, hallucinations, cognitive impairment) do NOT occur. This is a critical distinction from hyoscine hydrobromide, atropine, and dicyclomine.

The oral route produces fewer and milder adverse effects than the parenteral route because oral bioavailability is <1% — systemic exposure is negligible. Most adverse effects listed below are reported primarily after parenteral administration.

Frequency classification source: Derived from clinical trial data, post-marketing surveillance, and CDSCO/Sanofi Buscopan product insert data. Exact incidences vary by route and dose.

Very Common (≥10%):

Adverse Effect	System	Notes
Dry mouth (xerostomia)	GI / Oral	The most frequently reported adverse effect. After parenteral administration: very common (reported in 10–30% of patients). After oral administration: uncommon to rare (<1–2%) — because the drug is not systemically absorbed. Dose-dependent. Usually mild and transient (resolves within 1–2 hours after parenteral dose). More pronounced with repeated parenteral dosing. Not typically a reason to discontinue therapy.

Common (1–10%):

Adverse Effect	System	Notes
Tachycardia	Cardiovascular	Primarily after parenteral administration. Due to vagolysis (blockade of cardiac muscarinic M₂ receptors). Heart rate increase is typically 10–20 bpm. Usually transient (5–15 minutes after IV dose). Rarely clinically significant in healthy patients. May be significant in patients with ischaemic heart disease, heart failure, hyperthyroidism, or pre-existing tachycardia. Dose-response threshold: Clinically significant tachycardia (>20 bpm increase) is more likely at doses ≥40 mg IV. At the standard 20 mg IV dose, heart rate increase is usually modest. After oral administration: tachycardia is NOT expected (negligible systemic absorption).
Nausea	GI	Reported in 1–5% after parenteral administration. Paradoxical — since the drug is an antispasmodic, nausea may reflect the underlying condition rather than the drug itself. May also be related to the rapid IV bolus or transient hypotension.
Constipation	GI	Due to reduced GI motility (the intended therapeutic action can become an adverse effect if excessive). More relevant with repeated oral dosing (local antimotility effect in the colon) or parenteral administration. Dose-dependent. More likely with doses ≥60 mg/day oral. Usually mild. Worsened by: concurrent opioids, iron supplements, calcium channel blockers, immobility — common in Indian clinical scenarios (post-surgical patients, elderly on polypharmacy).
Dizziness / light-headedness	Cardiovascular / CNS	ℹ️ This is NOT a central (CNS) effect — it is due to transient hypotension from peripheral vasodilation after IV administration. Occurs in approximately 1–5% after IV bolus. Usually brief (resolves within 5–10 minutes). Not observed with oral dosing. Patient should remain supine or seated for 15 minutes after IV dose.
Injection site pain	Local	After IM injection — reported in 1–5%. Transient. Related to the low pH of the solution.

Uncommon (0.1–1%):

Adverse Effect	System	Notes
Urinary hesitancy / retention	Genitourinary	Primarily after parenteral administration. Due to detrusor muscle relaxation and increased bladder outlet resistance. More common in elderly males with BPH. Very rarely reported with oral dosing.
Blurred vision	Ophthalmic	After parenteral administration — due to ciliary muscle relaxation (mild cycloplegia) and mydriasis. NOT observed with oral dosing (negligible systemic absorption). Usually mild and transient.
Skin flushing	Dermatological	After parenteral administration — due to peripheral vasodilation from muscarinic blockade. Transient. More common at higher doses.
Reduced sweating	Dermatological	After parenteral administration — anticholinergic suppression of eccrine sweat glands. Clinically relevant in hot climate (India) — contributes to hyperthermia risk. NOT observed with oral dosing.

Dose-Response Thresholds:

Adverse Effect	Dose Threshold
Dry mouth	After IV: clinically noticeable at standard 20 mg dose; more severe at ≥40 mg. After oral: very rarely significant even at 80 mg/day.
Tachycardia	After IV: modest at 20 mg (10–15 bpm increase); significant (>20 bpm) at ≥40 mg. After oral: not observed at therapeutic doses.
Constipation	After oral: more likely at ≥60 mg/day with continued use beyond 3–5 days.
Urinary retention	After IV: risk increases with doses ≥40 mg and in predisposed patients (BPH, concurrent anticholinergics).

SERIOUS ADVERSE EFFECTS

⚠️ Rare but clinically important — may require immediate intervention, discontinuation, or hospitalisation.

Serious Adverse Effect	Approximate Frequency	Details	Action Required
⚠️ Anaphylaxis / severe hypersensitivity	Very rare (<1 in 100,000)	Reported primarily after parenteral administration (IV or IM). Presents as urticaria, angioedema, bronchospasm, hypotension, cardiovascular collapse. Cross-reactivity with other tropane alkaloids (atropine, hyoscine hydrobromide) is expected. More likely in patients with previous reactions to anticholinergic drugs.	⛔ Immediate discontinuation. Standard anaphylaxis management: IM adrenaline (epinephrine) 0.5 mg (adult), IV fluids, antihistamines, corticosteroids, airway management. Report to PvPI.
⚠️ Severe tachycardia / tachyarrhythmia	Rare (estimated <1 in 1,000 at standard doses)	Primarily after IV administration, especially at doses ≥40 mg or when combined with other chronotropic drugs (beta-agonists, theophylline). In patients with pre-existing cardiac disease, can precipitate angina, myocardial ischaemia, or haemodynamically unstable tachyarrhythmia.	Stop the drug. Continuous ECG monitoring. If haemodynamically significant tachycardia: IV beta-blocker (esmolol 0.5 mg/kg loading dose — available at most tertiary centres in India) or IV metoprolol 2.5–5 mg slowly. If SVT: vagal manoeuvres → adenosine 6 mg rapid IV push.
⚠️ Acute urinary retention	Uncommon — estimated 0.1–1% after parenteral dosing in predisposed patients	More likely in elderly males with BPH, patients on concurrent anticholinergics, and postoperative patients. Presents as painful suprapubic distension, inability to void, agitation. Can progress to bilateral hydronephrosis and post-renal AKI if unrecognised.	Urinary catheterisation (in-out or indwelling). Stop further anticholinergic dosing. Review prostate status. If recurrent, avoid anticholinergic drugs — use drotaverine or mebeverine.
⚠️ Paralytic ileus	Very rare at therapeutic doses; risk increases with concurrent opioids and in postoperative patients	Absent bowel sounds, progressive abdominal distension, obstipation, nausea/vomiting. Can progress to bowel ischaemia or perforation if unrecognised.	Stop all anticholinergic and opioid drugs. NG tube decompression. IV fluids. Surgical consultation if signs of peritonitis or perforation.
⚠️ Severe hypotension (after IV administration)	Uncommon (estimated 0.5–2% after IV bolus)	Transient hypotension is a recognised effect of IV hyoscine butylbromide. In most patients, it is mild and self-limiting (systolic BP drop of 10–20 mmHg). In hypovolaemic, dehydrated, or haemodynamically compromised patients, the drop can be more significant and may cause syncope, falls, or end-organ hypoperfusion.	Ensure adequate hydration before IV dosing. Administer slowly over 1–2 minutes. If significant hypotension occurs: Trendelenburg position, IV fluid bolus (500 mL NS rapid infusion). Usually self-resolving within 5–10 minutes. Vasopressors are almost never needed.
⚠️ Hyperthermia	Very rare; primarily in children, elderly, and hot climates (India)	Due to anticholinergic suppression of sweating after parenteral administration. Risk is compounded by fever, dehydration, high ambient temperature (>40°C in Indian summer), and concurrent anticholinergic drugs. Can lead to heat exhaustion or heat stroke if unrecognised.	External cooling measures, IV fluids, temperature monitoring. Stop the drug. Unlike hyoscine hydrobromide, physostigmine is NOT useful here because the toxicity is peripheral (hyoscine butylbromide does not cross BBB). Neostigmine (0.5–2.5 mg IV) may theoretically reverse peripheral anticholinergic effects including anhidrosis, but evidence is limited.
Allergic skin reactions	Rare	Rash, urticaria, pruritus — less severe than anaphylaxis. May occur with oral or parenteral administration.	Discontinue if rash develops. Antihistamines for symptomatic relief. If rash is severe or progressive (concern for SJS/TEN — though not reported with hyoscine butylbromide), stop the drug and manage accordingly.

Antidote Information — Anticholinergic Overdose:

Parameter	Details
Toxicity profile	ℹ️ Hyoscine butylbromide overdose produces peripheral anticholinergic toxicity ONLY — tachycardia, dry mouth, urinary retention, constipation/ileus, blurred vision, flushing, hyperthermia, and skin dryness. Central anticholinergic toxicity (delirium, hallucinations, seizures, coma) does NOT occur because the drug does not cross the blood-brain barrier. This makes hyoscine butylbromide overdose significantly less dangerous than overdose of tertiary amine anticholinergics (atropine, hyoscine hydrobromide, dicyclomine).
Antidote	Physostigmine salicylate — the standard antidote for anticholinergic toxicity — is NOT required and NOT recommended for hyoscine butylbromide overdose. Physostigmine crosses the BBB to reverse central anticholinergic effects — since hyoscine butylbromide does not cause central effects, physostigmine adds unnecessary risk (cholinergic crisis, bradycardia, bronchospasm) without central benefit.
Peripheral reversal	Neostigmine (0.5–2.5 mg IV, slowly) — a peripherally-acting cholinesterase inhibitor — may theoretically reverse peripheral anticholinergic effects (tachycardia, urinary retention, ileus). However, clinical evidence for neostigmine as a specific antidote for hyoscine butylbromide overdose is limited. Use only if peripheral effects are severe and life-threatening. Atropine (0.6 mg IV) should be available as a rescue if neostigmine causes excessive cholinergic effects (bradycardia, bronchospasm).
Supportive management	Mainstay of overdose management: IV fluids for hypotension/dehydration, external cooling for hyperthermia, catheterisation for urinary retention, NG decompression for ileus, continuous cardiac monitoring for tachyarrhythmia. Most cases resolve with supportive care alone.
Availability in India	Neostigmine injection is widely available in India (used routinely for reversal of neuromuscular blockade in anaesthesia). Physostigmine is available only at select tertiary centres.

⚠️ Report to nearest ADR Monitoring Centre under PvPI (Pharmacovigilance Programme of India) or via the ADR reporting form on CDSCO website — for ALL serious adverse effects listed above. Reporting can be done at: https://www.ipc.gov.in (Indian Pharmacopoeia Commission — National Coordinating Centre for PvPI).

MONITORING REQUIREMENTS

Baseline (Before Starting)

Parameter	Grade	Details
Clinical assessment for contraindications	MANDATORY	Specifically ask about: glaucoma history (narrow-angle?), prostate symptoms (urinary hesitancy, frequency, nocturia?), myasthenia gravis, known bowel obstruction. Rule out surgical abdomen before treating abdominal pain with antispasmodic.
Heart rate	RECOMMENDED	Document baseline heart rate before parenteral administration. Identify pre-existing tachycardia (>100 bpm) — relative caution for parenteral route.
Blood pressure	RECOMMENDED	Especially before IV administration — identify hypotension or hypovolaemia that may be worsened by IV hyoscine butylbromide.
Medication review	RECOMMENDED	Review for concurrent anticholinergic drugs (amitriptyline, chlorpheniramine, dicyclomine, oxybutynin, etc.) — assess cumulative anticholinergic burden. Review for solid oral KCl preparations (interaction).
Prostate symptom assessment (males ≥50 years)	RECOMMENDED (before parenteral dosing)	Ask about urinary hesitancy, poor stream, frequency. Simple IPSS questionnaire if time permits.
Serum electrolytes, renal function, liver function	OPTIONAL but helpful	Not required for oral tablets for self-limiting cramps. Recommended before repeated parenteral dosing in patients with suspected renal or hepatic impairment.
ECG	OPTIONAL	Not mandatory. Consider in patients with cardiac history before IV administration.
Abdominal imaging (X-ray/USG)	CONTEXT-DEPENDENT	MANDATORY if acute abdomen is suspected — rule out obstruction, perforation, appendicitis before attributing pain to “spasm.” NOT required for chronic/recurrent functional spasm in a patient with established IBS diagnosis.

Resource-limited setting surrogates:

Parameter	Surrogate
Heart rate / blood pressure	Palpate radial pulse for rate and volume. Ask about dizziness on standing (postural hypotension screen).
Prostate assessment	Ask 3 simple questions: “Do you have difficulty starting urination?” “Do you have to strain?” “Do you get up at night to urinate more than once?” — if all positive, use parenteral hyoscine butylbromide with extra caution and ensure catheterisation is available.
Abdominal imaging	Careful clinical examination: bowel sounds (absent in ileus/obstruction), peritoneal signs (rigidity, guarding, rebound tenderness), distension. If any peritoneal signs → refer for imaging. Do NOT give antispasmodic and reassess empirically.

After Initiation / Dose Change

Timing	Monitoring	Details
During and 15 minutes after IV administration	Heart rate, blood pressure	Check at 5 minutes and 15 minutes after IV bolus. If tachycardia >120 bpm or systolic BP drops >20 mmHg, continue monitoring for 30 minutes.
4–6 hours after parenteral dose	Urinary output	Confirm the patient has voided (especially elderly males, postoperative patients). If no voiding by 6 hours, assess bladder by palpation or ultrasound and consider catheterisation.
After 3–5 days of regular oral dosing	Bowel function	Ask about constipation. If constipation develops, consider reducing dose, adding fibre/laxative, or switching to mebeverine.

Long-Term / Maintenance Monitoring

Timing	Monitoring	Details
Every 2–4 weeks (if regular oral use for IBS)	Clinical review: symptom control, bowel habit, side effects	Reassess whether continued antispasmodic therapy is needed. Hyoscine butylbromide provides symptom relief only — if IBS symptoms are stable, consider trial of discontinuation. Monitor for constipation with prolonged use.
No routine blood tests needed	—	Hyoscine butylbromide does not cause haematological, hepatic, or renal toxicity. No blood monitoring required for chronic oral use.

Therapeutic Drug Monitoring (TDM)

Not applicable — hyoscine butylbromide does not have a defined therapeutic plasma concentration range, and TDM is not performed in clinical practice. The drug has a wide therapeutic index. Dosing is adjusted based on clinical response and tolerability.

When to Stop Monitoring

Single-dose parenteral use: Monitoring can be discontinued once the patient is haemodynamically stable, has voided, and has no signs of anticholinergic adverse effects — typically 2–4 hours after the dose.
Regular oral use: No ongoing monitoring is required beyond periodic clinical review of symptom control and bowel habit.

PATIENT COUNSELLING

Written in simple language that a doctor can directly convey to the patient during consultation.

What this medicine is for:

“This medicine relaxes the muscles in your stomach, intestines, and urinary passages. It stops painful cramps and spasms in your belly. It does NOT cure the underlying problem — it helps with the pain and discomfort.”

How to take it:

Tablets: “Swallow the tablet whole with a glass of water. Do not chew or crush it — it has a special coating to prevent bitter taste. You can take it with or without food, but taking it 30 minutes before meals may work better if your cramps are related to eating.”
Injection: “This will be given to you by a doctor or nurse in the hospital. You do not need to do anything.”
Suppository (if prescribed — rare): “Remove the foil wrapper completely. Insert the pointed end gently into the back passage (rectum). Try to keep it inside for at least 30 minutes.”

What to do if you miss a dose:

“If you forget to take a dose, take it as soon as you remember — unless your next dose is due within 3 hours. In that case, skip the missed dose. Never take two tablets together to make up for a missed dose. If you only take this medicine when you have pain (as needed), you do not need to worry about missed doses.”

Common side effects to expect:

"This medicine usually causes very few side effects when taken as tablets. You may notice:

Dry mouth — sip water frequently; this usually goes away on its own.
Mild constipation — eat fibre-rich foods (fruit, vegetables, whole grains) and drink plenty of water.
If you receive this medicine as an injection, you may feel your heart beating a little faster for a few minutes — this is temporary and usually not a problem."

ℹ️ “Good news: Unlike some similar medicines, this one does NOT make you drowsy or sleepy. You CAN continue to drive, work, and do your normal activities while taking the tablets.”

Warning signs — come to hospital immediately if you notice:

"⚠️ Go to the hospital immediately if you develop:

Inability to pass urine for more than 6–8 hours (especially if you have prostate problems)
Severe stomach pain that gets worse despite taking the medicine (this could mean a different problem that needs urgent attention)
Very fast heartbeat that does not settle, or chest pain
High fever with very dry, hot skin and no sweating (especially in summer)
Severe skin rash, swelling of face/lips/tongue, or difficulty breathing (this could be an allergic reaction — very rare)
Severe constipation with bloating and no passage of gas"

Things to avoid:

“There are no special food restrictions with this medicine.”
“Alcohol: This medicine does NOT interact with alcohol the way some other medicines do. However, alcohol may worsen your stomach symptoms, so moderate your intake.”
“⚠️ Hot weather (Indian summer): If you receive the injection form, avoid excessive heat exposure for a few hours after — the medicine can temporarily reduce your ability to sweat, which could make you overheat. Drink plenty of water and stay in a cool place.”
“Driving: You CAN drive while taking the tablets — this medicine does NOT cause drowsiness. However, if you feel dizzy after receiving the injection, wait until you feel normal before driving.”

Storage:

“Store tablets in the original blister pack in a cool, dry place at room temperature (below 30°C). In very hot weather, keep medicines in the coolest part of the house — not in the bathroom, not in a car, and not near a window. Keep away from children.”

Duration:

“This medicine is usually for short-term use — take it only when you have cramps, or for a few days at a time as your doctor advises. It is NOT usually needed lifelong. You can stop it any time without gradually reducing the dose — there is no ‘withdrawal effect.’”

Follow-up:

“If your cramps keep coming back despite taking this medicine for 5–7 days, see your doctor again — you may need further investigation (blood tests, ultrasound, or endoscopy) to find the cause of your pain. Do not keep taking this medicine for weeks without a doctor’s review.”

Common patient questions addressed:

Question	Answer
“Can I take this with my other medicines?”	“Tell your doctor about all medicines you are taking. This medicine is generally safe to combine with most common medicines. However, if you take medicines for prostate, glaucoma, or medicines that slow your bowel (like codeine/tramadol), tell your doctor — the combination may need monitoring.”
“Can I take this during fasting (Ramadan/Navratri)?”	“If you take the medicine only when you have pain (as needed), you can take it when cramps occur — even during the fasting period. If you take it regularly three times a day, adjust the timing to your eating schedule during the fast: take doses at Suhoor/pre-dawn meal, Iftar/evening meal, and before sleeping. Discuss with your religious guide if uncertain.”
“Will this affect my ability to drive or work?”	“No — this is one of the advantages of this medicine. Unlike some other stomach-cramp medicines (like dicyclomine), Buscopan does NOT make you sleepy. You can drive, work, and study normally while taking the tablets.”
“Is this medicine habit-forming?”	“No — this medicine is not addictive and does not cause dependence. You can stop it at any time.”
“Can I stop once I feel better?”	“Yes — this medicine is for symptom relief. You can stop as soon as your cramps settle. You do not need to complete a ‘course’ like an antibiotic.”
“Is this the same as Buscopan Plus?”	“Buscopan contains only the cramp-relieving medicine (hyoscine butylbromide). Buscopan Plus also contains paracetamol (a pain reliever). Your doctor will decide which one is more suitable for your type of pain.”
“Why didn’t the tablet work for my kidney stone pain?”	“The tablets work mainly inside the stomach and intestines. For kidney pain, the medicine needs to get into your bloodstream — which requires the injection form. That is why the doctor may give you an injection for kidney stone pain instead of a tablet.”

Caregiver / Family Counselling:

"If you are caring for an elderly patient or a child taking this medicine:

Elderly: Watch for inability to pass urine (especially elderly men with prostate problems), worsening constipation, or fast heartbeat after receiving the injection. Ensure adequate water intake. Keep the patient cool, especially in summer.
Children (≥6 years on tablets): The tablet must be swallowed whole — do not crush it. Make sure the child drinks enough water. Watch for stomach bloating, constipation, or reduced urination. Keep medicines out of children’s reach — the sugar-coated tablet may look appealing to younger siblings."

India-specific adherence support:

Concern	Guidance
Cost-driven non-adherence	“Buscopan brand tablets are affordable (₹2–4 per tablet). Generic hyoscine butylbromide is even cheaper. If cost is a concern, ask your doctor about generic alternatives or check Jan Aushadhi stores.”
Temperature-sensitive storage	“This medicine does not need a fridge. But keep it below 30°C — in Indian summers, keep medicines in an earthen pot (matka) or in the coolest cupboard in the house.”
Rural access	“If you cannot find hyoscine butylbromide at your local pharmacy, drotaverine (Drotin) is a similar cramp-relieving medicine that is very widely available across India. Ask your doctor if this is suitable for you.”
Self-medication culture	“ℹ️ This medicine requires a prescription in India. While it is relatively safe, abdominal cramps can sometimes indicate a serious condition (appendicitis, obstruction, ovarian torsion). See a doctor for proper diagnosis before starting any medicine for stomach pain.”

BRANDS AVAILABLE IN INDIA

Jan Aushadhi / PMBJP brands:

No dedicated Jan Aushadhi / PMBJP brand of hyoscine butylbromide (tablet or injection) is confirmed in the current PMBJP product catalogue. The drug is not part of the Jan Aushadhi scheme as of the reference date.

Private / Commercial brands — Tablets:

Brand Name	Manufacturer	Strength	Availability
Buscopan	Sanofi India	10 mg tablet	Widely available — the most recognised brand in India. Stocked across all tiers: metros, cities, towns, and many rural pharmacies. Very strong brand recall among prescribers and patients.
Buscopan Plus	Sanofi India	10 mg hyoscine butylbromide + 500 mg paracetamol (FDC)	Widely available — extremely popular FDC for menstrual cramps and abdominal colic. Often dispensed OTC in practice despite Schedule H classification.
Butyl (various manufacturers)	Multiple generic manufacturers	10 mg tablet	Moderately available — generic alternatives. Stocked in some pharmacy chains and hospital pharmacies. Less brand recognition.
Hyobut	Various manufacturers	10 mg tablet	Limited availability — available in some hospital pharmacies.

Private / Commercial brands — Injection:

Brand Name	Manufacturer	Strength	Availability
Buscopan Injection	Sanofi India	20 mg/mL, 1 mL ampoule	Widely available — stocked in most hospital pharmacies, emergency departments, endoscopy suites, and labour rooms across India. The dominant injectable brand.
Generic hyoscine butylbromide injection	Multiple Indian manufacturers	20 mg/mL, 1 mL ampoule	Available — stocked in government hospitals and some private hospitals. Often procured through government tenders at lower cost.

CDSCO NSQ / Recall Alerts: No specific Not of Standard Quality (NSQ) alerts or product recalls for hyoscine butylbromide products (Buscopan or generics) were identified at the time of this monograph. Prescribers should verify against the latest CDSCO notifications at https://cdsco.gov.in.

PRICE RANGE (INR)

Prices as of June 2025. Verify current prices on NPPA/1mg/PharmEasy/Jan Aushadhi price lists as prices may change.

Formulation	Strength	Approximate Price Range (INR)	Notes
Buscopan tablets (Sanofi)	10 mg (strip of 10)	₹35–50 per strip (₹3.50–5.00 per tablet)	Most widely used brand. MRP varies slightly by region.
Generic hyoscine butylbromide tablets	10 mg (strip of 10)	₹15–30 per strip (₹1.50–3.00 per tablet)	Significantly cheaper than branded Buscopan. Quality may vary — verify manufacturer credentials.
Buscopan Plus tablets (Sanofi)	HBB 10 mg + Paracetamol 500 mg (strip of 10)	₹50–70 per strip (₹5.00–7.00 per tablet)	Popular FDC. Slightly more expensive than Buscopan alone.
Buscopan injection (Sanofi)	20 mg/mL, 1 mL ampoule	₹20–35 per ampoule	Hospital supply price may be lower (₹10–20 per ampoule through government tenders).
Generic hyoscine butylbromide injection	20 mg/mL, 1 mL ampoule	₹8–20 per ampoule	Available in government hospitals at lower cost.

NPPA Price Control: Hyoscine butylbromide is NOT currently on the NPPA price-controlled list under the Drug Prices Control Order (DPCO) / NLEM scheduling. The drug is not listed in NLEM India 2022.

PMBJP (Jan Aushadhi) availability: Not available through Jan Aushadhi stores.

Per-Month / Per-Course Cost Estimates:

Scenario	Estimated Cost
IBS — chronic oral use at 10 mg TDS (30 days)	Branded (Buscopan): ₹315–450/month. Generic: ₹135–270/month.
Dysmenorrhoea — short course (3 days/month, 10 mg TDS)	Branded: ₹32–45 per cycle. Generic: ₹14–27 per cycle.
Acute colic — single IV dose (ED visit)	₹20–35 (Buscopan injection) + administration charges.
Buscopan Plus for dysmenorrhoea (3 days/month, 1 tab TDS)	₹45–63 per cycle.

ℹ️ Cost comparison with alternatives:

Drotaverine 80 mg tablet (Drotin, Lupin): ₹3–5 per tablet — comparable cost.
Mebeverine 135 mg tablet (Colospa, Abbott): ₹5–8 per tablet — slightly more expensive.
Dicyclomine 20 mg tablet (Cyclopam, Indoco): ₹1–2 per tablet — cheapest antispasmodic, but causes drowsiness.

CLINICAL PEARLS

💡 1. Oral hyoscine butylbromide works LOCALLY in the gut — NOT systemically. Oral bioavailability is <1%. This means: (a) Oral tablets are effective for GI spasm (local action on gut wall muscarinic receptors from the luminal side). (b) Oral tablets are NOT effective for renal colic, ureteric spasm, or biliary spasm — these require systemic drug levels achievable only via the parenteral route. Prescribing oral Buscopan for kidney stone colic is one of the most common prescribing errors in Indian emergency departments. [Evidence-based — pharmacokinetic data from product insert and Goodman & Gilman]

💡 2. This drug does NOT cause drowsiness — a major advantage over dicyclomine and hyoscine hydrobromide. Hyoscine butylbromide is a quaternary ammonium compound that cannot cross the blood-brain barrier. Patients can drive, operate machinery, work, and study while on oral hyoscine butylbromide. This makes it the preferred antimuscarinic antispasmodic for ambulatory patients, students, professionals, and anyone who needs to remain alert. Dicyclomine (Cyclopam) crosses the BBB and causes significant drowsiness in many patients. [Evidence-based — pharmacological principle; confirmed in clinical trials]

💡 3. Myth vs Fact — “Buscopan dilates the cervix and shortens labour.”
Myth: Hyoscine butylbromide injection is routinely given in Indian labour rooms to “dilate the cervix faster.”
Fact: Multiple Indian RCTs have been conducted, with heterogeneous results. Some show modest reduction in labour duration (1–3 hours); others show no benefit. A Cochrane review found low-to-moderate quality evidence. Drotaverine has better-quality evidence for this indication than hyoscine butylbromide. FOGSI has not formally endorsed routine use of hyoscine butylbromide for labour acceleration. Current best practice recommends evidence-based labour augmentation methods (oxytocin, amniotomy) rather than empirical anticholinergic use. If an antispasmodic is chosen for cervical dilation, drotaverine is preferred based on available Indian literature. [Evidence-based — Cochrane review, Indian RCTs, FOGSI practice]

💡 4. In palliative care for death rattle: hyoscine butylbromide does NOT sedate — choose your agent wisely. If the dying patient is agitated and concurrent sedation is desired, use hyoscine hydrobromide (crosses BBB → provides sedation + antisecretory effect). If the patient is still conscious and wishes to communicate, or if delirium is already present and you want to AVOID further sedation, use hyoscine butylbromide or glycopyrrolate (neither crosses BBB → antisecretory effect only, no sedation). Choosing the wrong agent can result in either under-sedation of an agitated dying patient or over-sedation of a conscious patient who wants to say goodbye. [Practice-based — IAPC palliative care guidelines, palliative medicine expert consensus]

💡 5. For IBS: mebeverine is better for long-term use; hyoscine butylbromide is better for acute cramps. Mebeverine (Colospa) is a direct smooth muscle relaxant (non-anticholinergic) with no systemic anticholinergic side effects, no antimotility effect (does not worsen constipation), and better suitability for chronic daily use in IBS. Hyoscine butylbromide is better for PRN use during acute IBS cramp episodes because of its faster onset and stronger antispasmodic action. For IBS-C (constipation-predominant), avoid hyoscine butylbromide (worsens constipation through antimotility effect) — use mebeverine instead. [Evidence-based — ISG IBS consensus; Practice-based — Indian gastroenterology experience]

💡 6. IV hyoscine butylbromide can cause transient HYPOTENSION — hydrate the patient first. This is an often-overlooked effect. In a dehydrated patient presenting to the ED with abdominal colic and vomiting, administering IV hyoscine butylbromide before adequate fluid resuscitation can drop the blood pressure significantly. Always start IV fluids first, then give the antispasmodic once the patient is adequately hydrated. This is especially relevant in Indian EDs during summer months when patients present with dehydration from gastroenteritis. [Practice-based — emergency medicine clinical experience; consistent with product insert warning]

VERSION

RxIndia v0.1 — 14 MAR 2026

REFERENCES

The following sources were used to compile this monograph. All text is originally written; no text was copied from any proprietary database.

CDSCO Product Insert — Buscopan (hyoscine butylbromide) tablets 10 mg and injection 20 mg/mL, Sanofi India Limited. Approved indications, contraindications, dosing, pharmacokinetics, and adverse effects for the Indian market. Most recently reviewed insert version (2023–2024).
CDSCO Product Insert — Buscopan Plus (hyoscine butylbromide 10 mg + paracetamol 500 mg), Sanofi India Limited. FDC-specific indications and dosing. Most recently reviewed insert version (2023–2024).
Indian Pharmacopoeia 2022 (IP 2022), Indian Pharmacopoeia Commission, Ghaziabad. 8th Edition. Monograph on Hyoscine Butylbromide Tablets and Injection — specifications and official standards.
National List of Essential Medicines (NLEM) India 2022, Ministry of Health & Family Welfare, Government of India. Hyoscine butylbromide is NOT listed. Dicyclomine is listed as an antispasmodic. Drotaverine is not listed.
Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 14th Edition (2023). Chapter 9: Muscarinic Receptor Agonists and Antagonists. Pharmacology of quaternary ammonium antimuscarinics — mechanism of action, distinction between tertiary and quaternary amines, pharmacokinetics (negligible oral bioavailability of quaternary ammonium compounds), peripheral vs central effects. Used for pharmacological depth; deferred to CDSCO product inserts for Indian-specific labelling.
Harrison’s Principles of Internal Medicine, 21st Edition (2022). Sections on irritable bowel syndrome, biliary colic, renal colic, and functional GI disorders — treatment references.
API Textbook of Medicine, 11th Edition (2019), Association of Physicians of India. Sections on IBS management, functional GI disorders, and abdominal colic. References antispasmodics as a treatment option for IBS without specifying a single preferred agent.
Indian Society of Gastroenterology (ISG) Consensus Statement on Irritable Bowel Syndrome (2018). Recommends antispasmodics for IBS-related abdominal cramps; lists hyoscine butylbromide, mebeverine, dicyclomine, and drotaverine as options.
Indian Association of Palliative Care (IAPC) Treatment Guidelines. Symptom management in terminal illness: management of death rattle (terminal respiratory secretions). Lists hyoscine butylbromide, hyoscine hydrobromide, and glycopyrrolate as antisecretory agents with guidance on agent selection.
Cochrane Database of Systematic Reviews — Antispasmodics in Labour. Samuels LA et al., Cochrane reviews on hyoscine butylbromide and drotaverine for cervical dilation. Referenced for Secondary Indication 1 (labour acceleration) and Clinical Pearl 3. Low-to-moderate quality evidence for modest benefit.
FOGSI (Federation of Obstetric and Gynaecological Societies of India) — Practice references and publications on labour management. No formal consensus guideline endorsing routine hyoscine butylbromide for cervical dilation was identified. Some FOGSI publications reference antispasmodics as an option, with drotaverine favoured in some publications.
IAP Textbook of Pediatrics, 6th Edition (2021), Indian Academy of Pediatrics. Sections on recurrent abdominal pain in children, functional abdominal pain disorders, and GI antispasmodic use in paediatrics.
Urological Society of India (USI) Guidelines on Urolithiasis. Referenced for renal colic management — NSAIDs as first-line with antispasmodics as adjunctive therapy.
Society of Gastrointestinal Endoscopy of India (SGEI) and Indian Society of Gastroenterology (ISG) — Endoscopy procedural protocols referencing hyoscine butylbromide as standard antispasmodic adjunct during upper GI endoscopy, colonoscopy, and ERCP.
American Geriatrics Society 2023 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. Lists “scopolamine (hyoscine)” as drug to avoid — clarified in this monograph as referring to hyoscine hydrobromide (crosses BBB), NOT hyoscine butylbromide (does not cross BBB). Used as additional reference for Elderly section.
STOPP/START Criteria version 2 (O’Mahony D et al., Age and Ageing, 2015; 44: 213–218). Referenced for antimuscarinic drug cautions in elderly patients.
Anticholinergic Cognitive Burden (ACB) Scale (Boustani M, Campbell N, Munger S et al., Aging Health, 2008; 4: 311–320). ACB score assignment — hyoscine butylbromide classified as ACB 1 (possible anticholinergic activity, minimal cognitive impact).
NPPA (National Pharmaceutical Pricing Authority) — Drug Prices Control Order (DPCO) schedule and ceiling price notifications. Hyoscine butylbromide is NOT currently price-controlled.
PMBJP (Pradhan Mantri Bhartiya Janaushadhi Pariyojana) — Product catalogue reviewed. No hyoscine butylbromide product currently listed.
CDSCO website (https://cdsco.gov.in) — Reviewed for banned FDC notifications, NSQ alerts, and product recall notices relevant to hyoscine butylbromide-containing formulations. No specific alerts identified for single-ingredient products.
PvPI (Pharmacovigilance Programme of India) — ADR reporting methodology referenced. IPC National Coordinating Centre, Indian Pharmacopoeia Commission.
Pallium India Training Modules — Essentials of Palliative Care. Drug formulary section referenced for antisecretory agent selection in terminal care.

⚖️

Clinical Responsibility

This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.

Content Feedback

Is this information helpful?

Help us improve our clinical database for the medical community.

RxIndia

Loading clinical data...